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Abstract
PLEASANT: Preventing and Lessening Exacerbations
of Asthma in School-age children Associated with a
New Term – a cluster randomised controlled trial and
economic evaluation
Steven A Julious,1* Michelle J Horspool,1 Sarah Davis,1
Mike Bradburn,1 Paul Norman,2 Neil Shephard,1 Cindy L Cooper,1
W Henry Smithson,3 Jonathan Boote,4 Heather Elphick,5
Amanda Loban,1 Matthew Franklin,1 Wei Sun Kua,1
Robin May,6 Jennifer Campbell,6 Rachael Williams,6
Saleema Rex1 and Oscar Bortolami1
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Department of Psychology, University of Sheffield, Sheffield, UK
3Department of Clinical Practice, University of Cork, Cork, Ireland
4Centre for Research in Primary and Community Care, University of Hertfordshire, Hatfield, UK
5Respiratory Department, Sheffield Children’s Hospital, Sheffield, UK
6Clinical Practice Research Datalink, London, UK
*Corresponding author s.a.julious@sheffield.ac.uk
Background: Asthma episodes and deaths are known to be seasonal. A number of reports have shown
peaks in asthma episodes in school-aged children associated with the return to school following the
summer vacation. A fall in prescription collection in the month of August has been observed, and was
associated with an increase in the number of unscheduled contacts after the return to school
in September.
Objective: The primary objective of the study was to assess whether or not a NHS-delivered public health
intervention reduces the September peak in unscheduled medical contacts.
Design: Cluster randomised trial, with the unit of randomisation being 142 NHS general practices, and
trial-based economic evaluation.
Setting: Primary care.
Intervention: A letter sent (n = 70 practices) in July from their general practitioner (GP) to parents/carers
of school-aged children with asthma to remind them of the importance of taking their medication, and
to ensure that they have sufficient medication prior to the start of the new school year in September.
The control group received usual care.
Main outcome measures: The primary outcome measure was the proportion of children aged 5–16 years
who had an unscheduled medical contact in September 2013. Supporting end points included the proportion
of children who collected prescriptions in August 2013 and unscheduled contacts through the following
12 months. Economic end points were quality-adjusted life-years (QALYs) gained and costs from an NHS
and Personal Social Services perspective.
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Results: There is no evidence of effect in terms of unscheduled contacts in September. Among children
aged 5–16 years, the odds ratio (OR) was 1.09 [95% confidence interval (CI) 0.96 to 1.25] against the
intervention. The intervention did increase the proportion of children collecting a prescription in August
(OR 1.43, 95% CI 1.24 to 1.64) as well as scheduled contacts in the same month (OR 1.13, 95% CI 0.84
to 1.52). For the wider time intervals (September–December 2013 and September–August 2014), there
is weak evidence of the intervention reducing unscheduled contacts. The intervention did not reduce
unscheduled care in September, although it succeeded in increasing the proportion of children collecting
prescriptions in August as well as having scheduled contacts in the same month. These unscheduled
contacts in September could be a result of the intervention, as GPs may have wanted to see patients
before issuing a prescription. The economic analysis estimated a high probability that the intervention was
cost-saving, for baseline-adjusted costs, across both base-case and sensitivity analyses. There was no
increase in QALYs.
Limitation: The use of routine data led to uncertainty in the coding of medical contacts. The uncertainty
was mitigated by advice from a GP adjudication panel.
Conclusions: The intervention did not reduce unscheduled care in September, although it succeeded in
increasing the proportion of children both collecting prescriptions and having scheduled contacts in
August. After September there is weak evidence in favour of the intervention. The intervention had a
favourable impact on costs but did not demonstrate any impact on QALYs. The results of the trial indicate
that further work is required on assessing and understanding adherence, both in terms of using routine
data to make quantitative assessments, and through additional qualitative interviews with key stakeholders
such as practice nurses, GPs and a wider group of children with asthma.
Trial registration: Current Controlled Trials ISRCTN03000938.
Funding details: This project was funded by the NIHR Health Technology Assessment programme and will
be published in full in Health Technology Assessment; Vol. 20, No. 93. See the HTA programme website
for further project information.
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Plain English summary
In the UK, the number of visits to the doctor by school-age children with asthma is high at the start ofthe new school term in September. During the summer holidays (i.e. in August), the number of visits is
lower and the number of asthma prescriptions collected also falls.
We wondered whether or not a letter from the general practitioner to the parents or carers of children
with asthma, reminding them to make sure that their children take their medication or to collect
prescriptions, could help prevent the children from being poorly. It suggested that parents should ensure
that their children’s medication is up to date and that they take it for at least 2 weeks before the school
return.
To see if the letter worked, we have undertaken a study in England and Wales. General practices were
randomly assigned either to sending out the letter (70 practices) or to continue with care as usual
(no letter, 72 practices) so that we could see if the letter had any effect.
We found there was an increase in the number prescriptions collected in August and medical contacts
such as asthma reviews. These increased contacts did not follow through to reduce the numbers of
children seeing their doctor or going to hospital in September, but there was evidence in October to
December of reduced contacts. These reduced contacts meant there was evidence of the letter saving
costs to the NHS.
General practitioners may wish to implement the intervention to increase prescriptions and scheduled
contacts in August. Evidence from the trial suggests that this would not increase costs associated with the
asthma management.
DOI: 10.3310/hta20930 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 93
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Julious et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi

Scientific summary
Background
Asthma episodes and deaths are known to be seasonal. A number of reports have shown peaks in asthma
episodes in school-aged children associated with the return to school following the summer vacation.
Children returning to school are exposed to a variety of novel respiratory insults, including allergens and
viruses, at a time of changing climactic conditions. It has previously been shown that viral infection and
allergen exposure in allergen-sensitised asthmatics are associated with increased hospital admissions for
acute asthma.
In previous research by members of our team, a random sample of approximately 75,000 school-aged
(5–16 years) children from England, Wales and Scotland, with a medical diagnosis of asthma, were
obtained from general practices within the General Practice Research Database [now the Clinical
Practice Research Datalink (CPRD)] to investigate the seasonal effect of asthma in a primary care setting.
Age- (within 2 years) and sex-matched controls (i.e. no asthma diagnosis) from the same practices were
also taken for comparisons.
This investigation confirmed the increase in unscheduled medical contacts in children with asthma
throughout the year, and a regression analysis showed that children with asthma were approximately
twice as likely as control children to have an unscheduled medical contact with their doctor around the
time of the return to school.
In the same study it was found that in August, immediately preceding the return to school, there were
25% fewer prescriptions for inhaled corticosteroids than in July and September. Furthermore, patients who
received a prescription for inhaled corticosteroids were less likely to have an unscheduled medical contact
after the return to school.
Objectives
The aim of the study was to assess if a NHS-delivered public health intervention [a letter sent from the
general practitioner (GP) to parents/carers of school-aged children with asthma] can reduce the number of
unscheduled medical contacts after the school return.
The primary objective of the study was to assess whether or not the intervention reduces the September
peak in unscheduled medical contacts.
Methods
The study was a cluster randomised trial to assess if a letter sent by a GP to the parents/carers of school-aged
children with asthma, reminding them to take their medication, reduces the number of unscheduled medical
contacts after return to school in September following the summer holiday. The unit of cluster was general
practices. Site recruitment commenced in January 2013, with the intervention being delivered during the
week commencing 29 July 2013. Data for the trial were collected via the CPRD.
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The effectiveness of the intervention was assessed on the basis of prescription uptake prior to the school
term and medical contacts thereafter. Analyses of medical contacts were defined in four overlapping
time intervals:
1. September 2013 (the primary study period)
2. September–December 2013 (the extended study period)
3. September 2013–August 2014 (the 12-month study period)
4. September 2014 (the echo substudy).
The primary study period was 1–30 September 2013, as this was the period when the intervention was
felt to be most likely be able to demonstrate an impact. The extended study period was 1 September–
31 December 2013, as asthma-related appointments are more frequent in these months. The full follow-up
period was 12 calendar months from 1 September 2013 to 31 August 2014. There is also an echo (or
follow-on) substudy period in September 2014 to see if the effect from September 2013 was maintained
when there was no actual study intervention.
Prescription uptake and scheduled medical contacts such as asthma reviews were evaluated during
three periods:
1. August 2013
2. August 2013–July 2014
3. August 2014 (the echo substudy).
The health economic analyses were based on a 12-month period from 1 August 2013 to 31 July 2014.
The period starts 1 month earlier than the evaluation of medical contacts in order to incorporate the cost
associated with delivering the intervention, including any increase in prescriptions or medical contacts in
response to the intervention that occurred during August 2013.
The primary outcome was the proportion of patients who had an unscheduled medical contact in
September 2013. The primary analysis population was the intention-to-treat (ITT) population among
children aged between 5 and 16 years.
The secondary outcomes evaluated included the number of unscheduled medical contacts in September
2013, and the number and proportion of any medical contacts (scheduled and unscheduled) in the same
time interval. The analyses of the same outcomes were repeated for the other time intervals.
The study was designed to detect a difference of 5% (30% vs. 25%) with 90% power and a two-sided
significance level of 5%, with an intraclass correlation of 0.03 to account for clustering. Based on this, we
estimated that we required 70 practices per arm. It was expected that the sample size of 140 practices
would equate to approximately 14,000 school-aged children with asthma.
The proportion of children having a medical contact was analysed separately for each time period using
logistic regression, in which the covariates were the individual’s age, sex, number of contacts the previous
September and the trial arm (intervention or control) as fixed effects, and the design/cluster effect of
general practice as a random effect. The proportion of children having a prescription within each time
period was analysed in the same manner.
The number of contacts, and the number of prescriptions, that each child had in each period were both
analysed using a random-effects negative binomial model, in which the same covariates as above were
included.
An economic evaluation was undertaken to estimate the cost-effectiveness of the intervention from an
NHS and personal social services perspective. The population for the economic evaluation was defined as
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school-aged children with asthma who are registered with a GP in England or Wales and, therefore, the
analysis was based on the Preventing and Lessening Exacerbations of Asthma in School-age children
Associated with a New Term (PLEASANT) study population. As the primary outcome for the PLEASANT
study was restricted to those children aged 5–16 years, this age subgroup was used for the base-case
cost-effectiveness analysis, with a subgroup analysis looking at children aged 4 years.
Setting
The setting was primary care, with the unit of cluster being general practices. Site eligibility required
practices to be using the Vision IT software [INPS (In Practice Systems), London, UK] and to be part of
CPRD. Site recruitment was conducted by CPRD and the National Institute for Health Research Primary
Care Research Network.
Participants
Participants were school-aged children with asthma, aged between 4 and 16 years, who were registered
with a GP.
Interventions
Sites were randomly allocated to either:
1. intervention group: sending out the letter
2. control group: standard care (no letter).
The intervention was a letter sent from a GP to the parents/carers of children with asthma, reminding
them to maintain their children’s medication, and to collect a prescription if they were running low. It also
advised that, should their child have stopped their medication, it should be resumed as soon as possible.
The letter template was developed based on standard letters already used in general practice. The wording
of the letter had input from the study team, which includes a GP, a health psychologist and a consultant
respiratory paediatrician, and was also discussed in detail at two patient and public events that included
school-aged children with asthma and their parents.
The intervention letters were sent out the week commencing 29 July 2013 to obviate the distraction of
planning for family holidays, and yet left enough time for parents and children to renew prescriptions and
gain benefit from the medication. The timing of the letter was decided following discussion with the
patient and public involvement group.
Results
In the primary analysis, the proportion of individuals who had at least one unscheduled medical contact
was 45.2% in the intervention arm, compared with 43.7% in the control arm [adjusted odds ratio (OR)
1.09, 95% confidence interval (CI) 0.96 to 1.25]. Similar results were observed across other subgroups, but
with wider CIs in the under-fives subgroups, reflecting the smaller number of children. The difference was
marginally greater for per-protocol than ITT analyses, and was marginally greater for children under
5 years old compared with those aged 5–16 years (ITT population). However, no statistically significant
difference was seen in any of the ITT comparisons.
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An objective with the PLEASANT study was that the intervention would increase the proportion of children
who had a prescription in August 2013, as it was shown in the earlier research that not collecting a
prescription was associated with unscheduled contacts in September. The intervention (letter) was
associated with an increased uptake of prescriptions in the month of August 2013. Among children aged
5–16 years, 876 (16.5%) had at least one prescription, compared with 703 (12.6%) in the control group
(adjusted OR 1.43, 95% CI 1.24 to 1.64); the total number of prescriptions was also higher (adjusted
incidence rate ratio 1.31, 95% CI 1.17 to 1.48). Scheduled contacts made in August 2013 also increased
(adjusted OR 1.13, 95% CI 0.84 to 1.52).
The increase in medical contacts in September may have been caused by GPs needing to see certain
patients before giving a new prescription. Evidence to support this is the observation that for children who
had collected a prescription within the last 3 months prior to the start of the study, there was no evidence
of an increase in unscheduled contacts in September; 56.4% in the intervention arm compared with
56.8% in the control arm. For patients whose last prescription was 3–6 months prior to the start of the
study, the excess was greater: 48.0% in the intervention arm against 42.9% in the control arm.
After September, there was evidence of a reduction in the mean number of unscheduled medical contacts.
The difference was small and not statistically significant.
The reduction in the medical contacts was reflected in the economic analysis (which used data over a
12-month period from August 2013 to July 2014), which estimated that the intervention had a 96.3%
probability of being cost-saving, with a mean cost saving of £36.07 per child in the base-case analysis for
5- to 16-year-olds when adjusting for baseline differences in costs between trial arms. There was no
associated increase in quality-adjusted life-years (QALYs).
Conclusions
The intervention did not reduce unscheduled care in September, which was the primary end point.
However, the intervention succeeded in increasing the proportion of children collecting a prescription in
August, along with the proportion of children who had scheduled contacts in the same month.
Over a wider time interval, there is weak evidence that the intervention reduced unscheduled medical
contacts. This is reflected in the health economic evaluation, which estimated a high probability that the
intervention was cost-saving. There was no increase in QALYs associated with this cost reduction.
Trial registration
This trial is registered as ISRCTN03000938.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Asthma episodes and deaths are known to be seasonal.1 A number of reports have shown peaks inasthma episodes in school-aged children associated with the return to school following the summer
vacation.2–10 These studies mainly report hospital admissions, although one study has reported peaks both
in hospital admissions and in other medical contacts.10
Children returning to school are exposed to a variety of novel respiratory insults, including allergens and
viruses, at a time of changing climactic conditions. It has previously been shown that viral infection and
allergen exposure in allergen-sensitised asthmatics are associated with an increased risk of hospital
admission for acute asthma. The same study demonstrated the protective effect of inhaled corticosteroids
on acute asthma exacerbations in a paediatric asthma population.11
In previous research by members of our team, a random sample of approximately 75,000 school-aged
(5–16 years) children from England, Wales and Scotland, with a medical diagnosis of asthma, were
obtained from general practices within the General Practice Research Database [now the Clinical Practice
Research Datalink (CPRD)12] to investigate the seasonal effect of asthma in a primary care setting. Age-
(within 2 years) and sex-matched control patients (i.e. no asthma diagnosis) from the same practices were
also sampled for comparison.13
This investigation confirmed the increase in unscheduled medical contacts in children with asthma
throughout the year, and a regression analysis showed that children with asthma were approximately
twice as likely as control children to have an unscheduled medical contact with their doctor around the
time of return to school in September. If children with asthma were at a constant increased risk of medical
contacts throughout the year, Figure 1 would show a random scatter of the residuals in England.13
However, around the time of return to school there is a pronounced positive increase in the value of
residuals. A similar pattern was observed in Scotland but with an earlier peak, which can be attributed to
school term starting 2 weeks earlier in Scotland than in England. These analyses indicate that, at this time,
there is a greater than expected increase in the number of unscheduled contacts by children with asthma
compared with control children.
We suggest that July and August are periods of reduced viral exposure (owing to reduced contact with
other children because of the holidays) and reduced pollen (antigen) exposure for children with asthma.
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FIGURE 1 Mean residuals for excess medical contacts for children with asthma for over control children in England.
The vertical lines represent, from left to right, 1 September, 1 January and 1 April.
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1
The reduced exposures could be an explanation for the observed drop in prescriptions for inhaled steroids
we found in August immediately preceding the return to school, with 25% fewer prescriptions in August
than in July or September (Figure 2, taken from Julious et al.13) This drop in prescriptions precedes the viral
challenge of a return to school. We further showed that patients who received a prescription for inhaled
corticosteroids had, on average, 0.14 fewer contacts than those who did not receive an August
prescription [England: 95% confidence interval (CI) 0.12 to 0.16 fewer contacts per patient; p < 0.001;
Scotland: 95% CI 0.10 to 0.18 fewer contacts per patient; p < 0.001].
To interpret the figure of 0.14, imagine a hypothetical cohort of 200 children with asthma on inhaled
corticosteroid, of whom 100 receive an August prescription and 100 do not. If the 100 patients with a
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FIGURE 2 Average number of inhaled steroid prescriptions by month for (a) England and (b) Scotland.
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prescription make a total of 50 unscheduled medical visits (0.5 mean visits/patient), then 64 unscheduled
medical contacts would be made by those not receiving a prescription (0.64 mean visits/patient; difference
0.14). Therefore, for every 100 children with asthma on inhaled corticosteroids not receiving a prescription
in August, there is an excess of 14 unscheduled medical contacts.
It is therefore possible that children who stop taking or reduce their inhaled corticosteroids over the
summer months, and/or who run low on other medications and fail to restart them before the return
to school, render themselves more vulnerable to an acute asthma exacerbation and unscheduled
medical contacts.
The cost to the NHS of unplanned medical contacts is £36 for a general practitioner (GP) surgery contact,
£121 for a GP home visit,14 £59–142 for an emergency department contact if not admitted and £74–249
if admitted, and £385 for a non-elective short stay for asthma without complications.15 The intervention/
letter therefore has the potential to benefit the health and quality of life of children with asthma while also
improving the effectiveness of NHS services by reducing NHS use in one of the busiest months of the year.
Research aims and objectives
The aim of the study was to assess if a NHS-delivered public health intervention (a letter sent from the GP
to parents/carers of school-aged children with asthma) can reduce the number of unscheduled medical
contacts after the school return.
The primary objective of the study was to assess whether or not the intervention reduces the September
peak in unscheduled medical contacts.
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Chapter 2 Methods
This report is concordant with the Consolidated Standards of Reporting Trials (CONSORT) statementextension for cluster randomised trials.16
Ethics approval and research governance
Ethics approval for the study was given by South Yorkshire Research Ethics Committee on 25 October 2012
(reference number 12/YH/04). NHS permissions to conduct the study were obtained for all the primary care
trusts in England and health boards in Wales.
The trial was registered with the International Standard Randomised Controlled Trial Number ISRCTN03000938.
Trial design
The study was a cluster randomised trial17 to assess if a letter sent by a GP to the parents/carers of school-aged
children with asthma, reminding them to take their medication, reduces the number of unscheduled medical
contacts after return to school following summer holiday in September. The unit of cluster was general
practices; site recruitment commenced in January 2013, with the intervention being delivered during the week
commencing 29 July 2013. Data for the trial were collected via the CPRD.
Clinical Practice Research Datalink
The CPRD GOLD is the world’s largest validated computerised database of anonymised longitudinal
medical records for primary care.18 Records are derived from GP software systems and contain complete
prescribing and coded diagnostic and clinical information, as well as information on tests requested,
laboratory results and referrals made at or following on from each consultation.19
The CPRD is thus able to capture all medical contacts, from prescription request through to out-of-hours
contacts, along with the reason for the contact. This therefore negated the need to request this
information from the individual GP practices.
Settings and locations where the data were collected
The setting was primary care, with the unit of cluster being general practices. Site eligibility required
practices to be using the Vision IT software [INPS (In Practice Systems), London, UK] and be part of CPRD.
Site recruitment was conducted by CPRD and the National Institute for Health Research (NIHR) Primary
Care Research Network.
Clinical Practice Research Datalink recruitment
Practice recruitment was carried out predominantly by CPRD. A practice recruitment pack, consisting of a
detailed study information sheet and an expression of interest (EoI) form, was sent to all 433 practices
contributing to CPRD in England and Wales at the time of recruitment. This was sent by post to the
preferred contact at the practice as specified in CPRD’s records for the practice. Non-responding practices
were sent a reminder e-mail, followed by a second reminder e-mail and then final reminders by e-mail and
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post. In addition to this, some practices were contacted by telephone, either by CPRD or by members of
the study team at the Sheffield Clinical Trials Research Unit (CTRU).
Practices that wanted to take part in the study, or to decline participation, returned the completed EoI form,
confirming or updating as necessary the information about the practice held by CPRD. Responses were
tracked by CPRD to ensure practices that had expressed interest or declined to participate were not contacted
again. The EoIs were then forwarded to the study team to contact practices and complete site set-up.
The details of the recruitment processes and contacts required to enrol GP practices have been published.20
National Institute for Health Research Primary Care
Research Network
The Primary Care Research Network also advertised and invited recruitment to the trial. Eligibility criteria
for general practices were that they were using Vision IT software and agree to be signed up to CPRD if
they were not already. Completed EoIs were returned to the study team for follow-up and site set-up.
Site set-up
The study team contacted interested practices to complete site set-up; this was done via telephone or
Skype™ (Microsoft Corporation, Redmond, WA, USA). Once set-up was complete and verbal consent
obtained from the practice to participate, practice details were forwarded to the study statistician for
randomisation. See Randomisation and blinding for details of randomisation.
Practices randomised to intervention group were sent GP packs that included the intervention letter
template, which was added to practice headed paper, with procedures on confirming patient eligibility and
instructions on the process and timing for delivery of the intervention via DocMail (www.cfhdocmail.com/;
accessed 18 January 2016; CFH Docmail Ltd, Radstock, UK).
Practices randomised to the control group were to continue with care as usual; no other activity was required.
Participants and eligibility criteria
Participants were school-aged children with asthma, aged between 4 and 16 years, who were registered
with a GP.
Inclusion criteria
Children were eligible if they:
l were aged between 4 and 16 years on 1 September 2013
l had a coded diagnosis of asthma
l had been prescribed asthma medication in the 12-month period from March 2012 to March 2013.
Exclusion criteria
Children were excluded if they:
l were aged 4 years or under on 1 September 2013 or 16 years or over on 31 August 2013
l were not considered appropriate for this intervention by their GP
l had asthma but were not receiving asthma medication
l had co-existing neoplastic disease.
METHODS
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The CPRD identified eligible participants based on pre-agreed diagnostic codes for asthma and the
inclusion/exclusion criteria, which were subsequently screened by the GP to confirm inclusion. The list of
diagnostic codes used by CPRD used for patient identification is available on the study Preventing and
Lessening Exacerbations of Asthma in School-age children Associated with a New Term (PLEASANT)
website: www.sheffield.ac.uk/scharr/sections/dts/ctru/pleasant/index (date last accessed 31 May 2016).
When writing this report it became apparent that there was a discrepancy between the code list provided
by the study team and the code list used by CPRD. The impact of this on the data extraction is discussed
in Changes to the data collection, data extraction and methods for allocation of data after the trial
commenced, with reasons.
Trial intervention
Sites were randomly allocated to:
1. intervention group: sending out the letter
2. control group: standard care (no letter).
For the intervention, a letter sent from a GP to the parents/carers of children with asthma reminding them
to maintain their children’s medication and collect a prescription if they are running low. It also advised
that, should their child have stopped their medication, it should be resumed as soon as possible (see
Appendix 1).
The letter template was developed based on standard letters already used in general practice. The wording
of the letter had input from the study team, which includes a GP, health psychologist and consultant
respiratory paediatrician, and was also discussed in detail at two patient and public events that included
school-aged children with asthma and their parents.21
The intervention letters were sent out during the week commencing 29 July 2013 to obviate the
distraction of planning for family holidays and yet left enough time for parents and children to renew
prescriptions and gain benefit from the medication. The timing of the letter was decided following
discussion with the patient and public involvement (PPI) group.21
Postal procedures
Practices were encouraged to use the DocMail service for sending the letters, which was done via a
website to secure servers. This was done, first, to reduce practice burden and, second, to allow monitoring
to confirm that the letters had been sent, the number of letters sent, and on which dates.
Practices that preferred not to use this method, and to arrange the posting themselves, were asked to
confirm that the letters had been posted, the dates and the numbers sent.
Outcomes
The effectiveness of the intervention was assessed on the basis of prescription uptake prior to the school
term and medical contacts thereafter. Analyses of medical contacts were defined in four overlapping
time intervals:
1. September 2013 (the primary study period)
2. September to December 2013 (the extended study period)
3. September 2013 to August 2014 (the 12-month study period)
4. September 2014 (the echo substudy).
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The primary study period spans from 1 to 30 September 2013, as this was the period when, prior to the
start of the study, the intervention was considered most likely be able to demonstrate an impact. The
extended study period was from 1 September to 31 December 2013, since asthma-related appointments
are more frequent in these months. The full follow-up period was 12 calendar months from 1 September
2013 to 31 August 2014. There was also an echo (or follow-on) study period in September 2014 to see if
the effect from September 2013 was maintained when there was no actual study intervention.
Prescription uptake and scheduled medical contacts were evaluated during three periods:
1. August 2013
2. August 2013 to July 2014
3. August 2014 (the echo substudy).
The health economic analyses were based on a 12-month period from 1 August 2013 to 31 July 2014.
The period starts 1 month earlier than the evaluation of medical contacts in order to incorporate the cost
associated with delivering the intervention including any increase in prescriptions or medical contacts in
response to the intervention that occurred during August 2013.
Primary outcome
The primary outcome measure was the proportion of patients who had an unscheduled medical contact in
September 2013. The primary analysis population was the intention-to-treat (ITT) population among children
aged between 5 and 16 years, but was repeated for other subgroups (see Analysis population for more details).
Secondary outcomes
The following outcomes were evaluated:
1. medical contacts during the primary study period (September 2013):
i. unscheduled medical contacts:
– the proportion of patients who had an unscheduled medical contact
– the number of unscheduled medical contacts.
ii. unscheduled medical contact associated with a respiratory diagnosis:
– the proportion of patients who had an unscheduled medical contact associated with a
respiratory diagnosis
– the number of unscheduled medical contacts associated with a respiratory diagnosis.
iii. any medical contacts (scheduled or unscheduled):
– the proportion of patients who had any medical contact
– the number of medical contacts.
2. medical contacts during the extended study period (September to December 2013):
– as for September 2013.
3. medical contacts during the 12-month study period (September 2013 to August 2014):
i. unscheduled medical contacts:
– the proportion of patients who had an unscheduled medical contact
– the number of unscheduled medical contacts
– the time to first unscheduled medical contact.
METHODS
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ii. unscheduled medical contact associated with a respiratory diagnosis:
– the proportion of patients who had an unscheduled medical contact associated with a
respiratory diagnosis
– the number of unscheduled medical contacts associated with a respiratory diagnosis
– the time to first unscheduled medical contact associated with a respiratory diagnosis.
iii. any medical contacts (scheduled or unscheduled):
– the proportion of patients who had any medical contact
– the number of medical contacts
– the time to first medical contact.
4. medical contacts during the echo period (September 2014):
– as for September 2013.
5. prescriptions and scheduled contacts in the month of August 2013:
– the proportion of patients who had a scheduled medical contact (e.g. asthma review)
– the number of prescriptions for preventative medications.
6. scheduled contacts in the 12-month period from August 2013 to July 2014:
– the proportion of patients who had a scheduled medical contact (e.g. asthma review).
7. prescriptions and scheduled contacts in the month of August 2014:
– as for August 2013.
Changes to trial outcomes after the trial commenced, with reasons
An additional secondary outcome has been added to include data up to September 2014 to evaluate
whether or not there was a carry-over effect into the following year. If the intervention were to increase
prescription uptake and reduce unscheduled medical contacts in the original study period, it would be of
interest to know whether or not the effect was repeated in the subsequent year without the need for a
repeat intervention. As routinely collected data were used throughout the study, there was no cost
associated with this extension. Therefore, the follow-up period was extended by 1 month. This was agreed
by the Trial Steering Committee (TSC) and NIHR Health Technology Assessment (HTA) programme as a
non-cost extension to the trial (see Appendix 2).
The non-cost extension also facilitated a survey of the GP practices that were in the intervention arm of the
study to inform the health economic evaluation of the study by asking questions on resource use in the
sending of the intervention letter.22
A second change concerned the analysis of adherence to medication. The planned statistical analysis
defined the medical possession ratio as the total number of days of prescriptions in the last year. During
the study it became clear that the CPRD data did not hold sufficient data to enable this analysis. The
amount of medication dispensed (e.g. the number of inhalers) is captured usually, but the amount of
medication required (e.g. the number of puffs an individual is required to take) is not. This information is
required to calculate the medical possession ratio. For this reason, our planned analyses of adherence were
not possible.
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Data collection, data extraction and methods for allocation
of data
Data were extracted from the December 2013 CPRD GOLD database build. Patients who were between
4 and 16 years of age on 1 September 2013 and currently registered at a participating practice were
considered for inclusion. A Read Code list, supplied by the study team at the Sheffield CTRU, was applied
to identify all patients who had a diagnosis code for asthma. The population was then limited to patients
who had been prescribed an asthma medication in the 12-month period of March 2012 to March 2013
using a Multilex code list. Patients who had a Read Code indicating neoplastic disease were excluded.
All data for the included patients were extracted from the database. In order to protect the identity of
included patients, the patient and practice identification numbers (IDs) were pseudonymised by the
research team at CPRD before the data were delivered to the CTRU. Read Code lists used for the data
extraction are available on request and are also on the website of the PLEASANT study at the following
address: www.sheffield.ac.uk/scharr/sections/dts/ctru/pleasant/index (accessed 31 May 2016).
Subsequent data extractions were done for the same patients on the April 2014, June 2014 and January
2015 builds in order to increase the length of follow-up.
Data handling
The primary data source was anonymised, and GP and NHS contacts extracted by the CPRD and forwarded
to the CTRU via a password-protected zip file.
Every NHS service contact is coded by the general practice and captured within the practice database.
These codes, which include diagnostic, consultation, prescription and test result codes, were used to
enable allocation to either scheduled or unscheduled contact. This allocation was carried out by presenting
a summary of the consultation codes, medcode descriptions and other tables used (as described in
Methods for allocation of data to scheduled/unscheduled contacts) to an independent GP adjudication
panel comprising three GPs. The GP adjudication panel reviewed the data and confirmed assumptions to
use in order to code contacts as scheduled, unscheduled or not applicable (not relevant). Detail and
definitions used for this coding are provided in the following section (see Methods for allocation of data to
scheduled/unscheduled contacts).
The age for inclusion in the study is age as of 1 September 2013. Day of birth is missing for all children
in the data set so there is no patient-identifiable information. For day of birth, the value ‘15’ was used.
If month of birth was also missing the value ‘September’ was used. The latter assumption was used because
data provided by CPRD have been checked for meeting the eligibility criteria, and hence subjects with a
missing month will be eligible with this month. All children with a missing month were born in the years
1997, 1998 and 1999. Thus assuming September, October, November or December for the missing months
ensures that all subjects born in 1997 are included in the analysis.
Note that the data were provided by CPRD as anonymised to prevent the identification of the children and
the practices in the study.
Given CPRD anonymisation of the practices, it was not possible to reconstruct the full disposition of some
children. For example, in the present report, 5917 children are allocated to the intervention arm and
6262 to the control arm in 141 practices, which is based on the data extracted from the database for the
analysis. In a different source (the original practice size listing used for the randomisation), 5907 subjects
are allocated to the intervention and 6431 to the control in 142 practices (including one practice, with a
size of 99, that subsequently withdrew its consent after randomisation – see Recruitment and participant
flow). Owing to the blinding, it was not possible to fully describe the discrepancy in numbers of children.
METHODS
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A similar issue is found with subject allocation to the per-protocol (PP) population. Although it is possible
to ascertain whether or not a subject is included in the PP population, because of blinding it was not
possible to fully link to the reason (e.g. ‘letter not sent’ or ‘letter sent late’) without a little interpolation.
Detailed data management processes are set out in a data management plan. Data will be retained in
accordance with the Data Protection Act 199823 and CTRU data management standard operating
procedures (SOPs).
Methods for allocation of data to scheduled/unscheduled contacts
A scheduled contact was defined as any contact that is part of the planned care for the patient, for
example an asthma review, a medical review, repeat prescription or immunisation. An unscheduled contact
was defined as any contact not part of the patient’s care plan that is either patient initiated or a result
of illness.
To ensure that the allocation of scheduled and unscheduled contacts was robust, a GP Adjudication Panel
comprising three independent GPs attended meetings to review the data blind to treatment. The GP
Adjudication Panel reviewed the unique terms (17% of the unique terms were reviewed, which accounted
for 90% of the data). During these meetings the GP Adjudication Panel devised the assumptions (i.e. rules)
used to allocate to scheduled, unscheduled or not applicable (irrelevant) contacts. These assumptions were
documented (see Appendix 3) and approved by the GP Adjudication Panel.
All types of ‘consultation’ are recorded within the data that CPRD provides; each consultation was
considered a medical contact. Not all consultations are considered relevant to the study. One ‘consultation’
in the consultation table was considered one contact. All consultation data supplied are taken into account
for the study, not just those that are asthma related. Only consultations that happened on or after
1 August were included.
Assumptions used to code records as scheduled, unscheduled or not applicable were based on a GP
Adjudication Panel review of the clinical, immunisation, therapy, referral, and test and consultation data.
The ‘medcode description’ from the clinical data was used first, as it was felt that this table gave most
description about the reason for the consultation. If contact type could not be determined by the
‘medcode description’, then clinical consultation was referenced.
Following the GP Adjudication Panel review of the medcode descriptions and clinical consultation types, in
which over 90% of the data were reviewed (17% of the unique terms), clinical records were identified to
be marked as scheduled (these include asthma annual review terms and other obvious types of planned
appointments), unscheduled (e.g. examinations, emergency appointments), not applicable or unknown.
The clinical data contain more than one record per consultation and the same consultation ID can have
more than one clinical contact type. For these clinical records, we assumed that unscheduled takes
precedence (i.e. they are likely to have come in for an unscheduled visit but had a scheduled ‘type’ of
procedure at the same time). Of all the contacts coded, a small proportion (2.27%, 10,011 of 440,429)
could have been defined as both, based on the assumptions made about the clinical data.
Consultation data marked as unknown, based on the clinical data, as well as consultation data that did
not link to clinical data, are coded based on immunisation, therapy, referral, and test and consultation
data. If at least one match was found in the immunisation record, then the data were coded as scheduled.
If at least one match was found with therapy (medication) data, then the data were coded as unscheduled.
If the data matched with the test data as part of the routine asthma review, then they were coded as
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scheduled. If they matched with test data of peak expiratory flow rate, then they were coded as unknown.
Otherwise, a match with test data was coded as unscheduled.
Finally, contacts were coded on the consultation type in the consultation table, where follow-up/routine visits,
repeat issue and medicine management were coded as scheduled; consultation types that indicated an
emergency visit were coded as unscheduled; administrative-type consultation types were coded as not
applicable; and those that were unclear, for example clinic, surgery consultation and other, were coded as
unscheduled because of the likelihood that most scheduled consultation types would be clearly recorded.
The process of allocation is detailed in Appendix 3.
Changes to the data collection, data extraction and methods
for allocation of data after the trial commenced, with reasons
When reviewing the code lists used by CPRD to identify patients, after the study was completed and it
was being reported, it became apparent that there was a discrepancy between the codes provided by the
study team and the codes used by CPRD. The missing codes included some asthma, neoplasm and
medication codes.
The clinicians on the Trial Management Group (TMG) reviewed the discrepancies between the codes used
by CPRD and those provided by the study team. With reference to the omitted asthma codes, the clinical
view was the codes were secondary codes and so there was no concern that children with asthma would
have been missed. For the omitted neoplasm codes, the clinical view was that there was no concern as the
codes were usually for adults and not children. However, there was a concern with the medication codes,
which had been on the original code list but which were omitted from the CPRD extraction. This is of
importance, as one of the inclusion criteria for the study was asthma medication prescribed in the previous
12 months. The clinical view was this may have resulted in fewer children having been identified as eligible
for the trial than should have been if the correct, full list of product codes had been used. The views of
the TMG, which were subsequently endorsed by the TSC, was that a further data extraction should be
undertaken by the CPRD to quantify the effect of using the correct medication code list compared with the
one used in error.
The CPRD undertook a review to identify the source of the problem and identified human error that was
not picked up in their quality assurance. The CPRD has amended its documentation and quality assurance
procedures to ensure that this type of human error is more readily identified and corrected at the time of
the mistake.
In response to the request by the TSC, the set of product codes supplied by the study team was used by
CPRD to identify those children with asthma who had received medication for asthma in the previous
12 months. This was done to estimate the magnitude of the impact upon the eligible patients. The CPRD
conducted a post hoc analysis identifying children aged between 4 and 16 years, and still registered
with a study practice, on 12 March 2013 using the April 2013 build of the CPRD GOLD database, utilising
both lists of product codes. This date and database were chosen as they were the most recent versions
documented to have been used for the identification of eligible patients for the trial. Owing to the human
error, it is not possible to exactly extract the same data set as used in the PLEASANT study. However, it
would give an estimate of the relative effect on the same size.
Using the CPRD list of medical codes, 10,753 children were identified, compared with 11,273 children
identified using the full list of medical codes. This equates to an estimated 5% of children with asthma
who potentially could have been in the trial but who were not. Thus, although this error has been
identified, it was unlikely to have a major impact upon the trial.
The error is unfortunate, but CPRD has introduced procedures to prevent such an error from happening again.
METHODS
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Sample size
From previous research in the CPRD practice population, 30% of school-aged children with asthma had
at least one unscheduled medical contact during the month of September.13 We postulated that the
intervention may reduce the number of children who have unscheduled medical contacts from 30% to
25% (i.e. an absolute reduction of 5%). The average practice size in the CPRD is 8294. Thus, we expected
c. 100 school-aged children with asthma per practice (based on 12% of a practice being school-aged
children and 11% of school-aged children having asthma). Therefore, to detect a difference of 5% with
90% power and two-sided significance level of 5%, and with an intraclass correlation (ICC) of 0.03 to
account for clustering, we required 70 practices per arm. The sample size of 140 practices would equate to
approximately 14,000 school-aged children with asthma.
Ukoumunne et al.24 give estimates of ICCs for patients with respiratory symptoms in general practice.
Based on the work of Ukoumunne et al., an ICC of 0.03 is a conservative estimate. The power of the study
for ICCs of 0.01, 0.02, 0.03, 0.04 and 0.05 was 99.4%, 96.0%, 90.0%, 83.1% and 76.2%, respectively.
As a further sensitivity analysis, we investigated the effect of practices not sending out the letter as
planned. Suppose 10 practices failed to send out the letter, these would still be included in the primary
analysis under the ITT principle. However, the effect that could be observed would be reduced to 4.3%.
Under the sample assumptions (ICC = 0.03, etc.), the power for the same sample size is reduced to
79.3%. This is a little under 80%, but it does demonstrate reasonable robustness to at least one deviation
in the planned design.
Randomisation and blinding
Randomisation was at cluster (general practice) level, and was stratified by size of general practice (i.e. the
‘list size’), to ensure that there was an equal sample size, in terms of number of school-aged children with
asthma, in each arm of the trial. The randomisation sequence was generated by the main trial statistician
based within the CTRU, and allocation concealment was ensured by restricting access to the two
CTRU statisticians. The randomisation was undertaken by a statistician within the CTRU, in line with a
study-specific randomisation plan. Once practices had agreed to participate, their identifier and list size
were forwarded to the trial statisticians for randomisation to one of the two groups (intervention or usual
care). The allocation was subsequently revealed to the study manager and research assistant.
The study team were unblinded throughout the study, but had no access to data until after a statistical
analysis plan was developed, and had no influence on data capture. The GP Adjudication Panels did not
have access to the randomisation group when reviewing the data.
Statistical methods
Analysis populations
Each of the outcomes listed in Outcomes were evaluated on each of the four subpopulations:
1. children aged 5–16 years (the primary analysis population)
2. children aged under 5 years
3. children aged 5–16 years with a prescription for steroid inhalers
4. children aged under 5 years with a prescription for steroid inhalers.
The choice of the 5–16 years age group as the primary analysis population is a result of the difficulty
associated with making a diagnosis of asthma among children below this age.25,26 Patients aged 4–5 years
were analysed separately to those aged 5–16 years, as the diagnosis of asthma is more controversial in the
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former age group; it is often not practical to measure variable airway obstruction below the age of 5 years,
making diagnosis of asthma difficult.25,26 The impact of the intervention in patients under 5 years will
be compared with that seen in the main analysis to assess whether or not the intervention appears to
benefit younger children. Additional analyses were restricted specifically to children who had received
a prescription for steroid inhalers in the previous year, again undertaken separately for children aged
5–16 years and under 5 years.
Analyses of effectiveness were performed on both ITT and PP bases, with the ITT being primary. The health
economic analyses were based on the PP population. ITT analyses included all practices for which data were
obtained by study period. The PP analyses were the subset of children in the ITT analyses to whom the
intervention was delivered as intended by the protocol. The two criteria for exclusion from PP analyses were:
1. Practices that did not send intervention letters as requested. In such cases, the entire practice data were
excluded from the PP analyses.
2. Individual children who were not sent the intervention letter. GPs were given discretion to withhold the
letter from any children they believed were unsuitable. In such cases, the individual was excluded from
the PP analyses.
Analytical methods
The proportion of children having an unscheduled medical contact was analysed separately for each time
period using logistic regression in which the covariates were the individual’s age, sex, number of contacts
the previous September and the trial arm (intervention or control) as fixed effects, and the design/cluster
effect of general practice as a random effect. The proportion of children having a prescription within each
time period was analysed in the same manner.
Both the number of unscheduled medical contacts made in each period by the children and the number of
prescriptions ordered within a time period were analysed using a random-effects negative binomial model
in which the same covariates as above were included.
Within each time period, the time to first medical contact was defined as the number of days from the start
of school term to the date of first contact. If no contact was made in the period, the time was censored at
the last date within the period. Analyses were conducted using Cox proportional hazards regression using a
random-effects (or ‘shared frailty’) model to account for the clustering within each practice. The same
covariates were used (i.e. age, sex, number of contacts the previous September and trial arm).
It should be noted that there was information on death status (no deaths were observed), but no
information about the movement outside GPs or region.
Full details of the analyses are in the statistical analysis plan (see Appendix 4).
Patient and public involvement
Patient and public involvement throughout the trial
Patient and public involvement during the conduct of the study had two components: (1) PPI consultations,
held in September 2012 and October 2015, that involved children with asthma and their parents; and
(2) two parents were invited to be independent members of the TSC.
Patient and public involvement consultation events
The September 2012 PPI consultation21 event was used to:
l Remind attendees of the purpose of the study and give feedback on outcome of the HTA
programme application.
METHODS
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l Discuss the adherence of the children to their medication over the school holidays and subsequently
since they have been back at school.
l Present the GP letter (trial intervention) that was discussed at a pre-funding PPI event in January 2011,
to show how it has changed as a result of the previous consultation and to invite further discussion on
how the wording of the letter could be improved.
l Invite comment on the design and end points to be used in the study and, in particular, on what, from
their perspective, is a scheduled and unscheduled contact.
l Discuss plans for PPI throughout the study and invite interested parents onto the TSC.
l Discuss the ethics application and the rationale of the research team for how the ethics of the study
are being addressed.
l Invite comment on the lay summary of the research ethics committee.
l Invite opinions on the study logo and the website.
The October 2015 PPI consultation27 was used to:
l recap the reason for the trial
l discuss the findings and any implications
l obtain advice from the children and parents on the interpretation of the findings
l give children and parents an opportunity to discuss how the findings should best be disseminated
l provide details of the next steps for the research
l consider any future research.
For attending the consultation events, each child was given a £20 gift voucher and parents were paid
travel expenses. Refreshments were also provided.28
Patient and public involvement members of the Trial Steering Committee
Two parents of children with asthma were invited onto the TSC. Payment for time was offered at a rate of
£50 per meeting, plus travel expenses. A glossary of key research terms used in the study was provided
and the study’s PPI lead was available to meet with the parent members of the TSC before or after each
meeting to discuss the agenda items and any issues of concern.
Trial oversight
Two committees were established to govern the conduct of the trial: the TMG and TSC.
All committees are governed by Sheffield CTRU SOPs. The TMG comprised the principal investigator,
co-investigators and key staff within the CTRU. The role of the TMG was to implement all parts of the trial.
The TSC comprised an independent chairperson (GP), two independent members (academic GP and
statistician), two lay members (parents of children with asthma), the principal investigator and key staff
within the CTRU (as non-voting members). The role of the TSC was to provide supervision of the protocol;
a statistical analysis plan; and to provide advice on, and monitor, the progress of the trial.
Safety assessments
The trial intervention aimed to optimise usual asthma care and improve adherence to medications already
prescribed by the GP, thus reducing the potential exacerbation of asthma following return to school in
September. Therefore, involvement in the trial was not expected to result in any adverse or serious adverse
events arising from participation.
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Any asthma complications relating to the health of the child were expected to be picked up by their GP
or out-of-hours service and managed as per usual care. On advice from the TSC, no formal reporting
procedures for adverse events or serious adverse events were put in place.
Practices randomised to the intervention were provided with a short template to report any incidents that
they felt were related to the conduct of the trial.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Chapter 3 Trial results
Recruitment and participant flow
In total, 142 GP surgeries agreed to take part in the study (Figure 3).20 Of these, one (a control group
practice with 99 children with asthma) withdrew consent after the start of the study for the data to be
extracted and stored by the CPRD (independent of the study); this practice was excluded from all analyses.
In total, 70 practices (comprising 5917 individuals) were randomised to the intervention (letter) group and
71 practices (6262 individuals) to the control group.
Baseline characteristics
The descriptive statistics (age, sex and surgery size) of the 12,179 subjects included are given in Tables 1
and 2. Summaries reported are stratified by intervention type and overall.
An analysis has been undertaken on practice recruitment into the trial. For the practices recruited through
CPRD, it was found that there was little difference in terms of the size of the practice.20 It was also found that
practices that have been involved in more research were more likely to be in the PLEASANT study, and that
the more studies the practice had previously participated in, the greater the likelihood of entering the trial.
Number of participants and analysis subsets
Analyses were conducted using outcome data from four overlapping time periods and one baseline period.
For each period, analyses were based only on practices that contributed data to the entirety of that period.
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In other words, if practices stopped submitting data to the CPRD before the end of a given follow-up
period, they were excluded from all analyses for that time period.
Figure 4 shows the flow of subjects from the overall population (aged 4–16 years) to the main cohort
(aged 5–16 years). Of the 456 practices invited, 433 were through the CPRD and 23 were through the
primary care research network and joined the CPRD.20
Table 3 provides the number of practices and the number of individuals aged 5–16 years (the primary
analysis population) included for each time period.
Adherence to protocol
Of the 70 intervention practices, two did not send letters to any of the patients identified and four sent the
intervention out late, on 6, 8, 12 and 23 August. In addition, GPs were given discretion to withhold the
letter from any children they believed were unsuitable candidates; among the remaining 64 practices
(5222 individuals), letters were not sent to 786 children. These individuals were included in the primary ITT
analyses but were excluded from the PP analyses.
TABLE 2 Descriptive statistics of surgeriesa
Statistic
Practice group
Total (n= 141)
Intervention (letter)
(n= 70)
Control (no letter)
(n= 71)
Sample size (n)
Mean (SD) 85 (44) 88 (SD 64) 86 (55)
Median (IQR) 80 (49–114) 75 (41–107) 76 (45–113)
Range 4–209 10–293 4–293
IQR, interquartile range; SD, standard deviation.
a Statistics produced at the surgery level.
TABLE 1 Descriptive statistics of patientsa
Statistic
Group
Total (n= 12,179)
Intervention (letter)
(n= 5917)
Control (no letter)
(n= 6262)
Sex, n (%)
Male 3505 (59.24) 3749 (59.87) 7254 (59.56)
Female 2412 (40.76) 2513 (40.13) 4925 (40.44)
Age (years)
Mean (SD) 10.51 (3.29) 10.55 (3.30) 10.53 (3.30)
Median (IQR) 10.80 (7.88–15.97) 10.89 (7.80–15.97) 10.89 (7.80–15.97)
Range 4.05–15.97 4.05–15.97 4.05–15.97
IQR, interquartile range; SD, standard deviation.
a Statistics produced at the subject level.
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FIGURE 4 The CONSORT diagram of the number of GP surgeries and individuals in the PLEASANT study. It is not a
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Outcomes and estimation
Primary outcome
Unscheduled medical contacts in September 2013
The proportion of individuals with at least one unscheduled contact is summarised for each of the four
populations (including the aforementioned primary analysis population) in Figure 5. Overall, 2399
individuals (45.2%) in the intervention arm had at least one unscheduled medical contact, compared with
2441 (43.7%) in the control arm [adjusted odds ratio (OR) 1.09, 95% CI 0.96 to 1.25]. The actual number
of contacts was similar in the two groups, but there were 81 unscheduled contacts per 100 children in
each arm [adjusted incidence rate ratio (IRR) 1.02, 95% CI 0.94 to 1.12]. Restricting the analyses to the PP
population gave a similar (but slightly greater) increase in the effect sizes.
The ICC for the primary analysis was 2.6%, which was consistent with the ICC used for the sample
size calculation.29
Similar results were observed for 5- to 16-year-old children who had been prescribed preventative steroids.
Among children aged under 5 years, the differences were larger, and of borderline statistical significance,
with the intervention being associated with more unscheduled visits for all subgroups. In all cases the
effect among the PP population was greater than that observed in the ITT population.
The percentage of children aged 5–16 years who required one or more unscheduled contact between
August and December 2013 is given in Table 4. The most immediate feature is the excess unscheduled
contacts in August 2013, which is out of keeping both with the following months and with the equivalent
figures in the previous year. Overall, the proportion of children making an unscheduled contact was higher
in 2012 than in 2013, but only August (and to a lesser extent, September) 2013 showed a pronounced
difference between the groups.
To further investigate the effect observed in Table 4, the analysis of unscheduled contacts by month was
repeated (Table 5), but only for children who received preventative medication. The effects are similar to
those observed in Table 4.
TABLE 3 Number of practices and individuals included within each time period
Time period
Group
Intervention Control
Practices (n)
Individuals
5–16 years (n) Practices (n)
Individuals
5–16 years (n)
Prescription uptake and scheduled medical contacts
August 2013 68 5305 69 5586
August 2013–July 2014 58 4541 54 4549
August 2014 58 4541 54 4549
All medical contacts
September 2013 (primary study period) 68 5305 69 5586
September–December 2013 (extended
study period)
65 5097 67 5384
September 2013–August 2014 (12-month
study period)
58 4541 54 4549
September 2014 (echo substudy) 57 4411 53 4438
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In both Tables 4 and 5, after the initial increase in unscheduled contacts associated with the intervention
in August and September there is a fall. The fact that there seems to be a reduction in contacts after
September will be discussed further in Chapter 3, Contacts in the extended post-intervention phase
(September to December 2013) and in Health economic methods.
In Scheduled visits and steroid prescriptions in August 2013, in the analysis of prescription data it will be
highlighted how the intervention caused an increase in the proportion of prescriptions being collected.
A likely explanation for the possible increase in August and September in the letter group is patients who
have not collected a prescription in a while needing to see their GP before a new prescription could be
given. This could be caused by patients wishing to see their GP or by the GP requiring an appointment
with the patient before a prescription is given. The excess observed in August/September would therefore
be, for some patients, a level of planned care that would then be reflected in the subsequent reductions in
following months. To investigate this we have the results in Table 6.
The results in Table 6 are the same data as in Table 5 but broken down by when a patient last collected a
prescription. There is little evidence of a difference in terms of the excess in unscheduled contacts in the
letter arm in August. For children who last collected a prescription within the previous 3 months, 51.6%
in the letter arm had an unscheduled contact in August, compared with 45.5% in the control arm,
therefore 6.1% more children in the letter arm had a scheduled contact. For children who had collected
a prescription within the previous 3–6 months, 38.5% in the letter arm had an unscheduled contact,
compared with 34.5% in the control arm, which represents a 4.0% excess.
In September there does seem to be a difference in the proportion of children having an unscheduled
contact according to when they last collected a prescription. If a prescription had been collected within
3 months, then in the letter arm 55.2% of children had an unscheduled contact in September, which is
comparable to the 54.3% in the control arm. Conversely, if it was 3–6 months since the last prescription
was collected, 42.1% of children had an unscheduled contact in the intervention arm, compared with just
TABLE 5 Percentage of children aged 5–16 years and using preventative medication who had at least one
unscheduled contact
Month
2012 (preceding year) 2013 (intervention year)
Intervention (%) Control (%) Intervention (%) Control (%)
August 41.9 41.3 39.0 34.1
September 47.8 48.9 43.2 41.5
October 52.0 52.0 42.7 43.5
November 52.1 50.9 41.5 40.5
December 49.9 50.0 39.9 38.5
TABLE 4 Percentage of children aged 5–16 years who had at least one unscheduled contact
Month
2012 (preceding year) 2013 (intervention year)
Intervention (%) Control (%) Intervention (%) Control (%)
August 41.8 41.0 41.1 34.4
September 47.4 48.2 45.2 43.7
October 51.4 50.0 44.5 45.8
November 51.5 50.1 43.7 44.3
December 49.0 49.1 42.2 41.8
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39.7% in the control arm, which is an increase of 2.4%. Therefore, the effect in September seems to be
greatest in children who had not collected a prescription recently.
One important thing to note is that when making the assessment of unscheduled contacts, we cannot
determine whether the unscheduled contact is at the request of the patient or of the GP. This factor is
important in the interpretation of the results in Tables 4–6.
Secondary outcomes
Scheduled visits and steroid prescriptions in August 2013
An objective of the PLEASANT study was that the intervention would increase the proportion of children
who had a prescription in August 2013, which would follow through to an increase in medication usage
and, thereby, a reduction in unscheduled medical contacts. Although the latter was not evident from the
data in Primary outcome, and adherence could not be assessed, the intervention (letter) was associated
with an increased uptake of prescriptions in the month of August 2013. Among children aged 5–16 years,
876 (16.5%) requested at least one prescription, compared with 703 (12.6%) in the control group
(adjusted OR 1.43, 95% CI 1.24 to 1.64); the total number of prescriptions was also higher (adjusted
IRR 1.31, 95% CI 1.17 to 1.48). These findings are displayed graphically in Figure 6.
Scheduled contacts made in August 2013 are displayed in Figure 7. The percentage of children with a
scheduled medical contact was higher in the intervention group compared with the control group
(see Figure 7a), but this was not statistically significant. The actual number of scheduled contacts were
significantly increased in the intervention group (see Figure 7b).
Unscheduled medical contacts associated with respiratory diagnosis in
September 2013
Unscheduled respiratory-related medical contacts are important, as these are the most sensitive outcome
for determining whether or not the intervention is preventing episodes of asthma exacerbation. In absolute
terms, however, these contribute only a small fraction of the total attendances (Table 7). Among the
primary ITT analysis population of children aged between 5–16 years, a total of 513 subjects experienced
at least one unscheduled respiratory-related contact across all practices, with slightly higher uptake in the
intervention group. In the intervention group, 279 (5.3%) required at least one unscheduled respiratory
related contact compared with 234 (4.2%) in the control group (adjusted OR 1.30, 95% CI 1.03 to 1.66).
The percentages for other subgroups are presented in Figure 8a, and the total number in Figure 8b.
TABLE 6 Percentage of children aged 5–16 years and using preventative medication who had at least one
unscheduled contact broken down by when they had their last prescription in the 12 months prior to the start of
the study
Month
Time period (%)
August–October 2012
November 2012–
January 2013 February–April 2012 May–July 2013
Intervention
(n= 385)
Control
(n= 385)
Intervention
(n= 645)
Control
(n= 670)
Intervention
(n= 738)
Control
(n= 813)
Intervention
(n= 1927)
Control
(n= 2004)
August 29.2 24.9 30.4 28.9 38.5 34.5 51.6 45.5
September 35.5 30.8 35.9 37.3 42.1 39.7 55.2 54.3
October 31.3 33.6 33.5 41.2 37.4 41.8 58.6 56.4
November 33.4 24.2 33.0 36.7 40.0 37.7 54.1 53.0
December 30.8 25.6 34.3 34.1 36.0 36.5 53.2 50.3
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All medical contacts (scheduled and unscheduled) in September 2013
The total number of medical contacts (excluding those deemed irrelevant) is presented in Figure 9.
In contrast to previous analyses, children in the intervention arm had fewer contacts, although, again,
none of the comparisons was statistically significant. Among children aged 5–16 years, 57.8% of the
intervention arm participants made one or more contact, compared with 58.4% of those in the control
arm (adjusted OR 0.99, 95% CI 0.80 to 1.22). The total number of appointments per child was 1.05 in
the intervention arm, compared with 1.10 in the control group (adjusted IRR 0.97, 95% CI 0.87 to 1.07).
Similar findings were observed for children on preventative steroids. By contrast, an increase in contacts
was observed among children under 5 years.
Contacts in the extended post-intervention phase
(September–December 2013)
Data on medical contacts in the extended study period (September–December 2013) were available for
65 of the original 70 intervention practices and 67 of the 71 control practices. The results are presented
in Figures 10–12. In some subgroups, a statistically significant excess of contacts was observed in the
intervention group, although it should be noted that this could be because of the multiple outcomes and
hypotheses tested.
The total number of unscheduled contacts is of particular relevance in the period September to December
2013. This includes the months (October to December) when the intervention arm seemed to reduce the
number of contacts. It is this time interval that forms part of the health economic analysis, which analyses
the total number of contacts rather than the percentage of children who required one.
The total number of contacts declined over the period from September to December. Although unscheduled
respiratory-related contacts demonstrated a slight increase, the proportion of children aged 5–16 years
requiring any medical contact remained higher in the intervention arm (although not statistically significant)
for unscheduled contacts (see Figure 10a), unscheduled respiratory contacts (see Figure 11a) and all contacts
(see Figure 12a). The overall number of contacts and the number of unscheduled was slightly reduced in the
intervention arm (see Figures 10b and 12b) for children aged 5–16 years, but not those aged under 5 years,
for whom the number of unscheduled respiratory contacts was also higher (see Figure 11b). However, these
differences were, generally, not statistically significant.
Contacts over 12 months (September 2013–August 2014)
Data on medical contacts in September 2013–August 2014 were available for 58 intervention practices
and 54 control practices. The results are presented in Figures 13–15. The differences in percentages
between the intervention and control groups were generally modest and not statistically significant on the
ITT population, and differed according to the subgroups. For the primary population (the ITT among 5- to
16-year-olds), the number of unscheduled contacts was similar (see Figure 13) and respiratory contacts
remained higher (see Figure 14), but overall, contacts were reduced (see Figure 15). The total number of
contacts over the 12-month period was 11.5 per child in intervention group, compared with 12.1 in
the control group, which equated to a 5% reduction overall (adjusted IRR 0.95, 95% CI 0.91 to 0.99).
This analysis is particularly relevant to the economic analyses in the following section, which primarily
considered the overall difference in resource costs between the groups and was largely based on this
time period.
Echo substudy
The protocol was amended to include additional outcomes for the subsequent year. We refer to this as the
‘echo substudy’, the rationale of which was to assess whether or not any immediate intervention effect in
2013 was echoed the following year. A total of 110 practices (57 intervention and 53 control) contributed
data to this time period.
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In a survey of the practices in the intervention it was found that, of those that responded, 54% (13 out of
24 responding practices) had sent out the intervention again in 2014.22 This would also contribute to an
echo effect
Steroid prescriptions and scheduled contacts in the echo substudy (August 2014)
Although the increase in prescriptions found in 2013 was not as marked in 2014, the under-fives subgroup
(i.e. children who were now aged under 6 years) did demonstrate an increase overall in terms of prescription
uptake. These findings are displayed graphically in Figure 16. Unexpectedly, the proportion of children
making at least one scheduled contact was lower in the intervention arm (Figure 17a). However, this
association disappeared when evaluating the total number of scheduled medical contacts (see Figure 17b).
Contacts in the echo substudy (September 2014)
The findings were similar to those of September 2013. Unscheduled contacts, unscheduled respiratory-related
contacts and scheduled contacts were all marginally higher in the intervention group (Figures 18–20), although
the size of the difference was more modest than that observed in the previous year.
Time to first unscheduled contact
The time to first unscheduled and respiratory-related unscheduled contacts are presented in Figure 21
(September 2013) and Figure 22 (September–December 2013). Consistent with the number of contacts as
previously demonstrated, the intervention group tended to make their first contact earlier than the control
group. As the majority of contacts were unscheduled, the time to first contact of any type was similar to
the time to first unscheduled contact.
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Chapter 4 Health economics
Health economic methods
Background
Asthma exacerbations in school-aged children have the potential to result in a reduction in health-related
quality of life (HRQoL) for the child and additional NHS resource use in either primary or secondary care if
the child presents with symptoms of an acute exacerbation. As the aim of the letter is to reduce the
incidence of asthma exacerbations associated with the new school term, the intervention has the potential
to result in both an improvement in HRQoL for children and cost savings for the NHS. There is, however,
an initial upfront cost of delivering the letter intervention, and those resources could be used to implement
other initiatives within the NHS. It was therefore important to consider not only whether the intervention is
clinically effective for the individual patient, but also whether or not adopting the letter intervention across
the NHS would be a cost-effective use of resources.
Overview
An economic evaluation was undertaken to compare the incremental cost per quality-adjusted life-year
(QALY) of the reminder letter compared with standard care. The population for the economic evaluation
was defined as school-aged children with asthma who are registered with a GP in England or Wales, and
therefore the analysis was based on the PLEASANT study population. As the primary outcome for the
PLEASANT study was restricted to those children aged 5–16 years, we have used this age subgroup for the
base-case cost-effectiveness analysis, and have done a subgroup analysis looking at children aged 4 years.
The perspective of the analysis was that of the NHS and Personal Social Services (PSS), although, as the
intervention is not expected to have any impact on PSS resource use, no costs for PSS were included in the
analysis. Both primary and secondary care NHS costs were included. We considered the benefits, measured
in QALYs, for the individual children included in the study and did not include any benefits falling on
parents, carers or other family members. The time horizon was 1 year from the intervention and, therefore,
no discounting was applied.
Unscheduled and scheduled contacts in the year following intervention were included in the economic
analysis to capture any change in health-care resource use in response to the letter. Prescriptions in the
year following the intervention for asthma medications used in the management of chronic asthma and
asthma medications used in the treatment of acute exacerbations were included to establish if the cost of
prescriptions had increased in response to the letter intervention. It was considered necessary to include
costs in the year following intervention rather than just in the first 4 months to distinguish between an
increase in the number of scheduled contacts and a change in the timing of the scheduled contacts.
The cost of the letter intervention was included for intervention practices with no cost included for
practices in the control arm, as standard care was assumed to be the same in both intervention and
control practices.
Measure of effectiveness for economic evaluation
Owing to the design of the trial, no data were collected directly from patients and, therefore, it was not
possible to directly determine the number, severity or duration of any acute asthma exacerbations
associated with the new school term. It was therefore necessary to estimate the number of asthma
exacerbations experienced from the routine data collected by the CPRD. As a single exacerbation may be
associated with more than one unscheduled contact, we needed to define the number of exacerbations
based on the pattern of unscheduled contacts. To do this, we split the 4-month follow-up period into
1-week intervals, and assumed that the patient was having an exacerbation in any week that included an
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unscheduled contact of any type. The intervention was assumed not to have any impact on exacerbations
after December.
Resource use
Data on the number and type of medical contacts in the intervention and control arms were collected
through the CPRD. As patients may present with multiple problems at a single contact, and the reason
for the contact is not always accurately coded, we have not restricted our analysis to respiratory-related
contacts. Although not all scheduled contacts in children with asthma will be related to their asthma
management, it is reasonable to expect that the number of contacts for other reasons will not differ
between the trial arms. We have therefore assumed in our analysis that any difference in the number
of scheduled or unscheduled contacts between the intervention and comparator arms is related to
the intervention.
For primary care contacts, the staff mix and duration of staff contact for each type of primary care contact
was estimated by clinical experts (clinicians on the TMG). For some unscheduled surgery visits and
emergency consultations, the estimates of resource use were stratified according to the severity of acute
exacerbation. The percentage having moderate, severe or life-threatening exacerbations was based on
clinical opinion and is shown in Table 8. The resource use estimates for primary care contacts are
summarised in Tables 9 and 10.
Data were also obtained from the CPRD on the number of prescriptions for medications used in the
management of chronic asthma and for medications used to treat acute exacerbations. A list of relevant
drugs was prepared in consultation with clinical experts, and these are shown in Table 11. The list of
antibiotics was restricted to those commonly used to treat respiratory infections associated with asthma
exacerbations in children. Although some drugs are used in the management of both chronic and acute
symptoms, they have been included in Table 11 under their primary use, but this has no implication for the
cost-effectiveness analysis, as drugs used for both indications are included in the total cost.
Information on the staff time required to deliver the letter intervention was based on the survey of
participating practices,22 which included questions regarding the staff members involved and the duration
of time required to complete the various tasks necessary to deliver the letter intervention across the eligible
population within a single practice. Resource-use data from the survey are summarised in Table 12.
The survey was undertaken as part of a no-cost extension of the trial (see Appendix 2).
Unit costs
For primary care contacts, the unit costs for scheduled and unscheduled patient contacts were taken from
Unit Costs of Health and Social Care 2014,30 and these are summarised in Tables 9 and 10. The Department
TABLE 8 Distribution of asthma severity by setting (estimated by clinical advisors)
Setting Exacerbation type Percentage
GP surgery Moderate asthma 70
Severe asthma 25
Life-threatening asthma 5
Emergency department Moderate asthma 20
Severe asthma 50
Life-threatening asthma 30
Hospital Severe asthma 60
Life-threatening asthma 40
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TABLE 10 Costing data for primary care contacts (other than unscheduled surgery visits/emergency consultations)
Scenario for
exacerbation
type
Staff
(ratio)
Range of
duration
(minutes)
Average
duration
(minutes)
Costs Weighted
average
of provider
costGPa Nurseb Administratorc
Unscheduled
clinic review
PN 15–30 22.5 – £19.88 – £19.88
Acute visit GP 10–15 12.5 £48.75 – – £48.75
Third-party
consultationd
NA – – – – – £212.00
Unscheduled
home visit
GP 15–30 22.5 £87.75 – – £87.75
Unscheduled
phone
consultation
PN : GP
(10 : 1)
– 5 £19.50 £4.42 – £5.79
Scheduled
phone
consultation
PN : GP
(10 : 1)
– 2 £7.80 £1.77 – £2.32
Scheduled
surgery
consultation
PN : GP
(2 : 8)
10–15 12.5 £48.75 £11.04 – £41.21
Scheduled
clinic review
PN – 30 £26.50 – – –
Medication
management
PN : GP
(25 : 75)
– GP, 2;
PN, 5
£7.80 £4.42 – £6.95
Administration Administrative
staff
– 0.5 – – £0.11 £0.11
Results
recording
Administrative
staff
– 0.5 – – £0.11 £0.11
N/A, not applicable; PN, practice nurse.
a £3.90 per minute of patient contact.30
b £53 per hour of face-to-face contact time including qualification costs.30
c £12.44 per hour.31
d Reference cost 258: paediatric respiratory medicine consultant-led non-admitted face-to-face attendance, follow-up.32
TABLE 11 Average cost per prescription for drugs included in the economic analysis
Drug class Drug or unique combination of drugs
Average cost per prescriptiona
(unit cost ×mean number of units)
Drugs used primarily in the management of chronic asthmab
Inhaled beta-2 agonist Salbutamolb £2.33
Salmeterol £34.66
Formoterol fumarate £27.16
Terbutaline £8.64
Inhaled corticosteroids Beclometasone dipropionate £6.71
Budesonide £14.29
Fluticasone £9.32
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TABLE 11 Average cost per prescription for drugs included in the economic analysis (continued )
Drug class Drug or unique combination of drugs
Average cost per prescriptiona
(unit cost ×mean number of units)
Leukotriene receptor antagonists Montelukastc £4.85
Zafirlukast £20.80
Theophylline Modified-release oral theophylline
(aminophylline/theophylline)
£5.42
Cromoglicic acid and related
therapy
Sodium cromoglycate Not prescribed within the data set
Nedocromil sodium £34.94
Combination inhalers Beclometasone dipropionate/formoterol
fumarate dihydrate
£32.25
Budesonide/formoterol fumarate dihydrate £44.27
Fluticasone propionate/formoterol fumarate £30.48
Fluticasone propionate/salmeterol xinafoate £32.64
Drugs used primarily in the management of acute asthma exacerbations
Antimuscarinic bronchodilators Ipratropium bromide £6.43
Oral corticosteroidsd Oral prednisolone £26.68
Drugs used in the treatment of respiratory infections associated with asthma exacerbations
Broad-spectrum penicillins Amoxicillin £1.40
Co-amoxiclav £4.85
Macrolides Clarithromycin £12.95
Erythromycin £7.61
Cephalosporins Cefaclor £5.68
Cefradine Not prescribed within the data set
Cefalexin £2.22
a Derived by combining information on the quantity prescribed and the list price.33
b Salbutamol is also used in the management of acute symptoms.
c Montelukast is sometimes used in the management of acute symptoms.
d Oral corticosteroids are used to manage chronic symptoms in some children.
TABLE 12 Resource use, unit costs and total costs for letter intervention
Activity, cost or staff
member
Staff Average cost
Practice
manager
Administrative
staff GP
Practice
nurse
Research
nurse
Per
practicea
Per
patienta
Unit cost per hour for
different staff membersb
£30.42 £14.15 £80.00 £0.42 £30.42 – –
Resource use and average cost per task
Database search
Time per practice
(minutes)
40 29 38 – – – –
Percentage of staff
involved (%)
38 46 17 – – – –
Weighted mean cost across staff £19.03 £0.22
continued
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of Health’s reference costs32 were used for secondary care contacts, and these are summarised in Tables 13
and 14. Drug costs were taken from the British National Formulary for Children August 2015.33 The average
cost per prescription (see Table 11) was calculated by combining data on the pack size (e.g. inhaler
containing 200 doses), the number of doses prescribed (e.g. 200 inhalations or one inhaler) and the unit
cost for each item. When more than 10 different preparations of the same drug were prescribed across the
whole data set, we have applied the average unit cost, weighted by frequency, from the 10 most commonly
prescribed preparations. Unit costs for the staff time associated with delivering the intervention were based
on the national costing template from the NIHR Primary Care Research Network’s Clinical Research Network
Industry Costing Template.31 Unit costs for materials and postage were based on commercial costs for
DocMail.34 The total average cost per patient was estimated by combining data on resource use, with the
unit costs as shown in Table 12.
Health outcomes
Owing to the design of the trial, no data were collected directly from patients and, therefore, it was not
possible to obtain direct estimates of health utility for the enrolled patients. Instead, these were obtained
indirectly from the estimated number of asthma exacerbations. Children experiencing an exacerbation
were assumed to have a utility decrement for the week of exacerbation, which was defined as any week
containing one or more unscheduled contacts.
TABLE 12 Resource use, unit costs and total costs for letter intervention (continued )
Activity, cost or staff
member
Staff Average cost
Practice
manager
Administrative
staff GP
Practice
nurse
Research
nurse
Per
practicea
Per
patienta
Checklist generated by search
Mean time per
10 patients (minutes)
6 9 6 7 10 – –
Percentage of staff
involved (%)
30 13 39 13 4 – –
Weighted mean cost across staff £44.31 £0.51
Mail-out process
Mail-out by DocMail
Time per practice
(minutes)
36 26 – – – – –
Percentage of staff
involved (%)
47 53 – – – – –
Weighted mean cost across staff types £11.92 £0.14
Mail-out by other process
Mean time per
10 patients (minutes)
15 13 – – – – –
Percentage of staff
involved (%)
14 86 – – – – –
Weighted mean cost across staff £31.21 £0.36
DocMail cost per letter/cost of postage plus materials for other mail-out process £33.69 £0.39
Average across DocMail and other mail-out processes (67% DocMail and 33% other) £18.34 £0.21
Total £115.38 £1.34
a Assuming 86 patients per practice.
b National institute for Health Research.31
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A systematic review of HRQoL data in children with asthma was conducted to identify appropriate sources
of data for patients with and without an exacerbation. Selection of utility data to use in the economic
analysis was based on (1) quality of the study, (2) the relevance of utility data to the population and health
states in the PLEASANT study and (3) the extent to which the measurement method was in accordance
with the National Institute for Health and Care Excellence (NICE) reference case.
The systematic review found that there was a lack of relevant and high-quality data on the impact of
exacerbations on HRQoL for school-aged children. Many of the studies in children did not estimate the
impact of exacerbation or used a less suitable measure of HRQoL, such as direct valuation or subjective
mapping from disease states to HRQoL. However, data were available for adults on the impact of
exacerbations estimated using NICE’s preferred instrument, the European Quality of Life-5 Dimensions
(EQ-5D).35 We considered that the estimates for exacerbations in adults may underestimate the degree
of utility loss in children with a severe or life-threatening acute exacerbation during the period of
hospitalisation, so alternative estimates that were considered to provide an upper limit on the utility
decrement attributable to exacerbation in children were explored in a sensitivity analysis. The systematic
TABLE 13 Unit costs for emergency department attendances by severity of asthma exacerbation
Exacerbation type Code
Healthcare Resource
Group Investigations Treatment
Unit
costa
Moderate asthma
presenting to
emergency department
VB09Z Emergency Medicine,
category 1 investigation
with category 1–2
treatment (type 1
non-admitted)
None i.v. cannula, guidance
advice, inhalers, oral
prednisolone
£102
Severe asthma
presenting to
emergency department
VB06Z Emergency medicine,
category 1 investigation
with category 3–4
treatment (type 1
non-admitted)
Capillary blood
gas
Administration of drug via
spacer or nebuliser,
supplemental oxygen, oral
prednisolone
£128
Life-threatening
asthma presenting to
emergency department
VB43Z Emergency medicine,
category 2 investigation
with category 4 treatment
(type 1 non-admitted)
Capillary blood
gas, chest
radiography
Nebulisation, guidance
advice, vital signs
monitoring, radiograph
review, CPAP, supplemental
oxygen, administration of
infusion or subcutaneous
drug
£224
Weighted average for all emergency department attendances £152
CPAP, continuous positive airway pressure; i.v. intravenous.
a Sourced from the National Schedule of Reference Costs 2013–14: NHS Trusts and NHS Foundation Trusts.32
TABLE 14 Unit costs of hospital admission
Reference cost details Frequencya Unit costb
PD12C: Non-elective short stay: paediatric asthma or wheezing, with a CC score of 0 15,159 £559
PD12B: Non-elective short stay: paediatric asthma or wheezing, with a CC score of 1–3 8390 £579
PD12A: Non-elective short stay: paediatric asthma or wheezing, with a CC score of ≥ 4 392 £572
Weighted average across all non-elective short-stay admissions £566
CC, complications or comorbidities.
a Frequency has been based on activity recorded for the Healthcare Resource Group within the national schedule of
reference costs.
b Sourced from the National Schedule of Reference Costs 2013–14: NHS Trusts and NHS Foundation Trusts.32
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review and rationale for selection of model inputs is further detailed in Appendix 5 and the data applied in
the model are summarised in Table 15.
The QALYs accrued per patient in the 4 months following the intervention (from 1 September to
31 December) were estimated using the area under the curve method. We assumed that the intervention
would have no impact on QALYs gained outside this 4-month period. We have also assumed that the
intervention had no impact on mortality.
Analysis
The health economics analysis was restricted to the PP patient group for whom CPRD data were available
over the period of analysis (1 August 2012 to 31 July 2014). The PP patient group was used, as these are
TABLE 15 Health state utility values to be applied in the economic evaluation
Health state
Health utility
value
Description of state from
source study Measurement Source
Base-case scenario
No exacerbation 0.96 (SD 0.07) Average baseline utility
across children (n= 27) aged
7–18 years with GINA
severity stage I to III
receiving standard
outpatient care in the
Netherlands as part of the
control arm of a RCT
EQ-5D child version
(filled out by parent
for children aged
< 12 years). UK adult
TTO valuation set
Willems et al.36
Exacerbation not
requiring hospitalisation
(including those
managed in the
emergency department)
–0.10 relative to
no exacerbation
Adult patients enrolled in a
prospective observational
study who have moderate
or severe asthma (BTS/SIGN
stage 4/5) at baseline and
who have experienced one
exacerbation requiring oral
steroid treatment (without
hospitalisation) in the
previous 4 weeks (n= 22)
EQ-5D UK adult
valuation set
LLoyd et al.37
Exacerbation requiring
hospitalisation
–0.20 relative to
no exacerbation
Adult patients enrolled in a
prospective observational
study who have moderate
or severe asthma (BTS/SIGN
stage 4/5) at baseline who
have experienced one
exacerbation requiring
hospitalisation in the
previous 4 weeks (n= 5)
EQ-5D UK adult
valuation set
LLoyd et al.37
Sensitivity analysis
No exacerbation As per base case As per base case As per base case As per base case
Any exacerbation –0.216 relative to
no exacerbation
Patients aged over 12 years
(including adults) enrolled in
the GOAL study38 who
experienced an exacerbation
(defined as deterioration in
asthma requiring treatment
with an oral corticosteroid,
or an emergency
department visit or
hospitalisation)
AQLQ values
mapped to EQ-5D
(valuation set not
stated)
Briggs et al.38
AQLQ, Asthma Quality of Life Questionnaire; BTS, British Thoracic Society; GINA, Global Initiative for Asthma;
GOAL, Gaining Optimal Asthma ControL; RCT, randomised controlled trial; SD, standard deviation; SIGN, Scottish Intercollegiate
Guidelines Network; TTO, time trade-off.
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the patients who actually received the intervention and for whom resource use information was available
within the CPRD for the time period of interest and, therefore, this group better predicts the costs and
benefits of implementing the intervention in clinical practice. The average cost per patient was calculated
by combining the resource use estimates with unit costs. This resource use is based on all ‘tasks’ recorded
in the CPRD data set, which could be face-to-face contacts (surgery visits), non-face-to-face contacts
(e.g. telephone calls) or general administrative tasks (i.e. recording letters sent to the surgery). In addition
to reporting the average cost per patient, we have also reported the breakdown of costs of intervention
costs, scheduled contacts, unscheduled contacts, prescriptions for chronic asthma management and
treatment of acute exacerbations. This breakdown is reported by mean value and distribution statistics [for
number of tasks, the mean, standard deviation (SD) and range are reported; for costs, the mean, 95% CIs,
median and range are reported]. The mean number of acute exacerbations per patient has been reported
in addition to the average QALYs accrued per patient. A statistically significant difference in resource use
or costs was assessed by using the t-test assuming unequal variance (because of the unequal sample sizes
between the letter intervention and no-letter groups). Statistical significance is defined as a p-value below
0.05 when describing statistical significance associated with 95% CIs for the outcomes of the economic
evaluation. We have defined statistical significance as p < 0.1 when assessing baseline imbalances.
Quality-adjusted life-years were calculated for the 4-month post-intervention time period, and costs were
calculated for 1 year post intervention. Utilities were assigned using a Markov assumption, whereby the
4-month post-intervention time period was split into 17 1-week time periods and one 3-day period
(accounting for the 122 days from 1 September to 31 December). It was assumed that, if an unscheduled
contact occurred within any particular week, a utility decrement for exacerbation was applied dependent
on the type of contact (see Table 16). The utility decrement for an exacerbation resulting in hospitalisation
overruled a non-hospital-related exacerbation utility value such that the most severe utility decrement for a
given exacerbation week was applied to the whole week. QALYs were calculated using the area under the
curve method39 based on the assumed exacerbation time period using Equation 1:
qjti =
(uj(t −1)i + Ujti)
2
δt, (1)
where u is the utility score, i denotes an individual and t is time so that at baseline t = 0. For each group j
[j = 0 for the no-letter group (control) and j = 1 for the letter group (intervention)], the consecutive time
measures are added, averaged and then rescaled (δ) for the percentage of a year that t and t – 1 cover,
which in this case was 0.019 (7 days in a week divided by 365.25 days in year) for the 17 1-week time
periods and 0.008 (3 days divided by 365.25 days in year) for the last 3 days in December. The total
QALYs (Q) for the 4-month estimation period (T) was the summation of the utility values at all 18 time
points starting at t = 1, the first week period, such that
Qji =∑
T
t = 1qjti. (2)
Patient costs were adjusted by 1-year baseline costs [baseline adjusted (BA)] using bootstrapped ordinary
least squares regression models (1000 replications) with 1-year baseline costs and intervention group as
covariates in the model, as recommended by van Asselt et al.40 Non-parametric bootstrapped estimation was
employed for unadjusted patient costs and QALYs, also using 1000 replications. Clustering at the practice
level with random effects was accounted for in the bootstrapped analysis. Unadjusted (observed) and
adjusted (BA, accounting for baseline costs) results are reported for mean and incremental values as
well as the bootstrapped standard error (SE), and bias corrected and accelerated (BCa) 95% CIs41 for all
post-bootstrap estimations. For the BA mean cost estimations (not the BA incremental results), the reported
SE are the delta method SEs, which are appropriate for adjusted/transformed cost approximations,42 and
normal 95% CIs. The main structural uncertainty analyses in reference to sensitivity analysis and subgroup
analysis are summarised in Table 16.
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Health economic results
Descriptive statistics of number of exacerbations, resource use and unit costs
A total of 8190 patients (letter group, n = 3641; no-letter group, n = 4549) were defined as being a part of
the PP patient group and had data available over the analysis period of 1 August 2012 until 31 July 2014; it
is these 8190 patients who were the focus of the health economic analysis. A summary of the number of
exacerbations per patient, as well as resource use and associated costs per patient by classified resource
use type (i.e. scheduled or unscheduled), prescription costs and overall costs, is presented in Table 17.
A detailed summary of patient resource use and associated costs by task, as reported in the CPRD data set
(reported in alphabetical order based on the task type), is presented in Table 18 (A–H; i.e. ‘acute visit’ to
‘hospital admission’) Table 19 (L–O; i.e. ‘letters from outpatient’ to ‘out-of-hours practice’) and Table 20
(R–W; i.e. ‘radiology result’ to ‘walk-in centre’).
The estimated number of exacerbations for the 4-month QALY estimation period (that period for which
a utility decrement was attached to these exacerbations) is dependent on the assumed period of
exacerbation, which was 1 week for the base-case analysis (the period of exacerbation was varied to
3 days or 2 weeks as part of the sensitivity analysis). The mean number of exacerbations per patient, as
presented in Table 17, was not statistically significantly different between the letter and no-letter groups
for this 4-month period (2.50 vs. 2.41, respectively; p = 0.078). These results suggest that over the
4-month period, on average, patients in the letter group spent 2.5 weeks in an exacerbated state and the
patients in the no-letter group spent just under 2.5 (2.41) weeks in an exacerbated state.
The resource use and associated cost results, as presented in Table 17, suggest that those patients in the
no-letter (control) group had more scheduled tasks over the 12-month post-intervention period than the
TABLE 16 Summary of sensitivity analysis and subgroup analysis
Model aspect varied Base-case scenario Sensitivity scenarios Rationale
Unit cost for contact types
defined as ‘other’
Unit cost of £0.11,
assuming that ‘other’ are
undefined administrative
tasks
Pooled weighted unit
cost of £45.58 based
on the recorded
resource use for all
contacts and
associated unit costs
excluding ‘other’ tasks
It is uncertain if these ‘other’
consultation types are
administrative
Duration of period used to
define exacerbation
1 week 3 days 2 weeks The average duration of symptoms
for an exacerbation is uncertain
Utility values for
exacerbation
–0.1 for non-hospital and
–0.2 for hospitalisation
following exacerbation
–0.216 relative to no
exacerbation
The utility decrement relative to no
exacerbation is uncertain
Type of contacts included All contacts regardless of
whether or not they are
respiratory related
Respiratory-related
contacts
Contacts coded as respiratory
related are more likely to be
affected by the intervention but a
large proportion of contacts could
not be coded as respiratory or
non-respiratory related
QALY and cost estimation
period
QALYs estimated for
4 months and costs for
1 year post intervention
QALY estimated for
4 months and costs
for 5 months post
intervention
To assess the shorter-term
(5-month) cost implications of the
intervention
Age of population
receiving intervention
Children aged 5–16 years Children aged
< 5 years
To assess the cost-effectiveness of
the intervention for children aged
< 5 years
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letter (intervention) group (2.69 vs. 2.60 tasks, respectively; p = 0.130), but the difference was not
statistically significant. The cost for scheduled tasks was also higher on average for the no-letter group, but
was not statistically significantly different (£169 for letter vs. £173 for no letter; p = 0.623). The reverse
was true for those tasks that were classified as ‘not relevant’. These ‘not relevant’ tasks were not classified
as either ‘scheduled’ or ‘unscheduled’ but were included in the economic analysis as part of the resource
use and cost estimations. The letter group had statistically significant more ‘not relevant’ tasks than the
no-letter group (mean number of tasks of 4.17 for letter vs. 3.75 for no letter; p < 0.001), but again this
did not translate into statistically significant different costs associated with these tasks (£204 for letter vs.
£205 for no letter; p = 0.915). There was no statistically significant difference in the number of unscheduled
tasks between groups (p = 0.867). There was a statistically significant lower mean cost for unscheduled
tasks in the letter group (£266 for letter vs. £283 for no letter; p = 0.030). There was no statistically
TABLE 17 Mean number of exacerbations for 4 months and resource use and cost for 12 months post intervention
per patient by intervention group
Variable and
statistics Variable type
Group Significant
difference
(p-value)Intervention Control
Mean number of
exacerbations,a mean
(SD), range
Number of exacerbations
when exacerbation period
was 1 week
2.50 (2.19), 0–14 2.41 (2.19), 0–16 0.078
Number of tasks,b
mean (SD), range
Scheduled tasks 2.60 (2.72), 0–22 2.69 (2.85), 0–30 0.130
Unscheduled tasks 9.39 (8.32), 0–73 9.36 (9.22), 0–101 0.867
‘Not relevant’ tasks 4.17 (4.79), 0–45 3.75 (4.73), 0–60 < 0.001
Total number of tasksc 16.16 (13.30), 0–120 15.80 (14.42), 0–163 0.249
Mean costs, mean
(95% CI), median
(range)
Scheduled tasks £169 (£158 to £181),
£27 (£0–3857)
£173 (£163 to £183),
£41 (£0–3839)
0.623
Unscheduled tasks £266 (£255 to 277),
£146 (£0–4661)
£283 (£272 to 294),
£186 (£0–8010)
0.030
‘Not relevant’ tasks £204 (£191 to £217),
£1 (£0–£6149)
£205 (£193 to £218),
£1 (£0–£7675)
0.915
Total task costd £639 (£612 to £667),
£342 (£0–£8829)
£662 (£636 to £688),
£358 (£0–13,411)
0.251
Prescriptions £55 (£52 to £59), £20
(£0–849)
£49 (£47 to £52), £16
(£0–789)
0.003
Total task and prescription
coste
£695 (£666 to £723),
£402 (£0–8921)
£711 (£684 to £738),
£412 (£0–13,484)
0.420
Intervention £1.34 £0 –
Overall resource use costf £696 (£668 to 3725),
£403 (£1–8922)
£711 (£684 to £738),
£412 (£0–13,484)
0.460
a Number of exacerbations’ is dependent on the assumed period of exacerbation, that is, 1 week. Therefore, for the letter
group, for example, there was a mean number of 2.5 exacerbations (2.5 weeks spent in an exacerbated state) over the
assessed 4-month period for which a utility value was attached.
b The mean number of tasks is provided to give descriptive information about the number of tasks per patient that were
included in the costing analysis, and for which a utility decrement could have been attached (unscheduled tasks only).
These figures should not be interpreted in relation to the more detailed clinical analysis focused on unscheduled events.
c Total number of tasks= the number of scheduled tasks plus the number of unscheduled tasks plus the number of ‘not
relevant’ tasks per patient.
d Total task cost = the cost for scheduled tasks plus the cost for unscheduled tasks plus the cost for ‘not relevant’ tasks
per patient.
e Total task and prescription cost = total task cost plus the cost for the prescriptions per patient.
f Overall resource use cost = the total task and prescription costs plus the cost of the intervention per patient.
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significant difference between the letter and no-letter groups in either the overall number of tasks
(p = 0.249) or associated costs (p = 0.251).
The results presented in Tables 18–20 suggest that there were some statistically significant (p < 0.001)
differences in the types of tasks and associated costs that defined the patients’ resource use over the
12-month post-intervention time period between the letter and no-letter groups. For example, the no-letter
group had a statistically significant lower number of casualty attendances [51 (1.40%) people from the letter
group had a casualty attendance, compared with 6 (0.13%) from the no-letter group]. This resulted in a
statistically significant mean higher cost of £2.84 vs. £0.30 for the letter compared with the no-letter group
(see Table 18). Tasks such as ‘co-op surgery consultation’, ‘co-op telephone advice’ and ‘follow-up/routine
visit’ were mainly associated with the no-letter group, with no recorded entry of these tasks for the letter
group (see Table 18). Surgery consultations occurred statistically significantly more often in the no-letter
group, which translated into a statistically significantly higher mean cost per patient associated with these
tasks of £174 for the no-letter group compared with £146 for the letter group (see Table 20).
Tasks recorded as ‘other’ occurred statistically significantly more often in the letter group than in the
no-letter group, with 53.5% of the letter group having a recorded ‘other’ task, compared with 45.1% in
the no-letter group. Among patients for whom an ‘other’ task was recorded (defined as ‘resource users’),
the number of tasks defined as ‘other’ was higher in the letter group than in the no-letter group (on
average, 4.1 tasks per patient in the letter group compared with 3.4 tasks per patient in the no-letter
group). This resulted in a statistically significant higher mean cost of £0.24 for the letter group compared
with £0.17 for the no-letter group. Although this difference is very small when a unit cost of £0.11 is
assigned to this ‘other’ task, larger unit costs being assigned to ‘other’ tasks could have an impact on the
cost-effectiveness of the letter group, as tasks classified as ‘other’ occur significantly more often for this
group (this aspect has been assessed as part of the sensitivity analysis; see Table 16).
The costs associated with prescriptions were statistically significantly different (p = 0.003) between groups,
with the mean cost for prescriptions being approximately £55 for the letter group and £49 for the
no-letter group, for the 12-month post-intervention period.
Although there appears to be a pattern of resource use and associated costs between the letter and
no-letter group, this did not translate into significantly different costs between the groups as a whole
(see Table 17).
Mean and incremental costs and quality-adjusted life-years from main, adjusted and
sensitivity analyses
The mean, SE and 95% CI for costs and QALYs by intervention (letter) and control group (no letter) are
presented in Table 21; the incremental results (mean difference for the intervention group minus control
group and distribution statistics) are presented in Table 22. BA results are presented alongside the
unadjusted results. It should be noted that there was a statistically significant difference (p < 0.1) in overall
costs at baseline (12 months before intervention) between the trial arms (these baseline results are
presented in Appendix 10, Table 40).
For the main unadjusted analysis, the mean observed cost and number of QALYs gained was £696.24 and
0.31594, respectively, in the letter group and £710.98 and 0.31611, respectively, in the no-letter group.
For the BA main analysis, the adjusted mean costs were £684.39 and £720.46 for the letter and no-letter
groups, respectively. From these results, it can been seen that the baseline adjustment had an important
effect on the cost results. The influence of the baseline adjustment on the cost results is discussed further
in Strengths and weaknesses of the economic analysis.
As presented in Table 22 for the main analysis, the incremental QALY loss for the letter group was
0.00017, with a cost saving of £14.74 or £36.07 for the unadjusted and adjusted cost analysis,
respectively. These mean point estimates were surrounded by large amounts of uncertainty. For example,
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TABLE 21 Mean and distribution statistics by cost and QALY per patient for main analysis, adjusted analysis,
sensitivity analysis and subgroup analysis
Analysis
Letter
(yes/no)
Cost QALYs
Mean SE 95% CIa Mean SE 95% CIa
Main Yes £696.24 £23.11 £649.31 to £740.98 0.31594 0.00013 0.31567 to 0.31619
No £710.98 £20.81 £670.07 to £752.73 0.31611 0.00012 0.31585 to 0.31631
BA main Yes £684.39 £17.08 £650.93 to £717.86 0.31594 0.00013 0.31567 to 0.31619
No £720.46 £12.33 £696.29 to £744.64 0.31611 0.00012 0.31585 to 0.31631
Sensitivity analysis: ‘other’ unit cost
Cost Yes £794.72 £27.19 £747.51 to £853.65 0.31594 0.00013 0.31567 to 0.31619
No £780.53 £24.07 £733.49 to £826.41 0.31611 0.00012 0.31585 to 0.31631
BA cost Yes £770.99 £18.74 £734.26 to £807.72 0.31594 0.00013 0.31567 to 0.31619
No £799.52 £13.91 £772.26 to £826.79 0.31611 0.00012 0.31585 to 0.31631
Sensitivity analysis: duration of exacerbation
3 days Yes £696.24 £23.11 £649.31 to £740.98 0.31843 0.00006 0.31830 to 0.31855
No £710.98 £20.81 £670.07 to £752.73 0.31848 0.00006 0.31835 to 0.31858
BA 3 days Yes £684.39 £17.08 £650.93 to £717.86 0.31843 0.00006 0.31830 to 0.31855
No £720.46 £12.33 £696.29 to £744.64 0.31848 0.00006 0.31835 to 0.31858
2 weeks Yes £696.24 £23.11 £649.31 to £740.98 0.31236 0.00022 0.31190 to 0.31276
No £710.98 £20.81 £670.07 to £752.73 0.31270 0.00020 0.31226 to 0.31304
BA 2 weeks Yes £684.39 £17.08 £650.93 to £717.86 0.31236 0.00022 0.31190 to 0.31276
No £720.46 £12.33 £696.29 to £744.64 0.31270 0.00020 0.31226 to 0.31304
Sensitivity analysis: utility of exacerbation
Utility Yes £696.24 £23.11 £649.31 to £740.98 0.31048 0.00028 0.30989 to 0.31100
No £710.98 £20.81 £670.07 to £752.73 0.31083 0.00025 0.31028 to 0.31126
BA utility Yes £684.39 £17.08 £650.93 to £717.86 0.31048 0.00028 0.30989 to 0.31100
No £720.46 £12.33 £696.29 to £744.64 0.31083 0.00025 0.31028 to 0.31126
Sensitivity analysis: type of contacts
Respiratory Yes £123.17 £4.98 £114.10 to £133.39 0.31999 0.00004 0.31992 to 0.32006
No £120.76 £6.87 £108.90 to £136.88 0.32007 0.00003 0.32001 to 0.32013
BA respiratory Yes £119.02 £3.17 £112.80 to £125.23 0.31999 0.00004 0.31992 to 0.32006
No £124.08 £3.17 £114.42 to £133.74 0.32007 0.00003 0.32001 to 0.32013
Sensitivity analysis: cost estimation period
5 months Yes £322.70 £9.64 £303.47 to £341.75 0.31594 0.00013 0.31567 to 0.31619
No £318.96 £11.15 £298.17 to £340.84 0.31611 0.00012 0.31585 to 0.31631
BA 5 months Yes £317.17 £7.03 £303.40 to £330.94 0.31594 0.00013 0.31567 to 0.31619
No £323.38 £7.13 £309.40 to £337.35 0.31611 0.00012 0.31585 to 0.31631
Subgroup analysis: under-fives
Under-fives Yes £1006.21 £120.73 £798.09 to £1289.15 0.31397 0.00049 0.31285 to 0.31485
No £809.30 £53.23 £722.15 to £932.29 0.31500 0.00038 0.31407 to 0.31561
BA under-fives Yes £906.71 £67.80 £773.82 to £1039.59 0.31397 0.00049 0.31285 to 0.31485
No £871.01 £50.85 £771.35 to £970.67 0.31500 0.00038 0.31407 to 0.31561
a All unadjusted SE are bias corrected and 95% CIs are BCa based on estimates post bootstrap; however, adjusted SE are
delta method SEs and 95% CIs are normal 95% CIs.
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the uncertainty around the incremental adjusted main analysis of a mean cost saving of £36.07 was a SE
of £21.10 and 95% CI ranging from a cost saving of £77.11 up to an additional cost of £9.67. For the
main analysis (QALY loss of 0.00017), the SE for the incremental QALY was 0.00018 and the 95% CI
ranged from a QALY loss of 0.00051 up to a QALY gain of 0.00018.
In the sensitivity analyses using BA costs, the letter was always shown to result in a mean cost saving,
although the difference never achieved statistical significance. However, in the sensitivity analyses using the
observed unadjusted costs, the letter resulted in an additional cost on average, albeit still non-statistically
significant, in all of the sensitivity analyses in which costs were affected. For the under-fives subgroup
analysis, a cost increase was identified in the unadjusted and adjusted analyses of £196.11 and £35.69 per
person, respectively. In general, for the adjusted analysis, the letter group was shown to be cost-saving at
the mean point estimate for the main and sensitivity analysis.
Across the main, sensitivity and subgroup analyses, a QALY loss was observed for the mean point estimates
ranging from a QALY loss of 0.00005 when the period of exacerbation was reduced from 1 week to 3 days
up to 0.00102 in the under-fives subgroup analysis. All incremental and mean point QALY estimates were
surrounded by large amounts of uncertainty, as presented in Tables 21 and 22.
TABLE 22 Summary of incremental results by cost and QALY per patient for the main analysis, adjusted analysis
and sensitivity analysis and subgroup analysis
Analysis
(1 – 0)a
Cost QALYs
Difference in
means SE BCa 95% CI
Difference in
means SE BCa 95% CI
Main –£14.74 £31.25 –£75.86 to £45.19 –0.00017 0.00018 –0.00051 to 0.00018
BA main –£36.07 £21.10 –£77.11 to £9.67 –0.00017 0.00018 –0.00051 to 0.00018
Sensitivity analysis: ‘other’ unit cost
Cost £14.19 £36.86 –£56.22 to £95.34 –0.00017 0.00018 –0.00051 to 0.00018
BA cost –£28.53 £23.64 –£72.74 to £20.18 –0.00017 0.00018 –0.00051 to 0.00018
Sensitivity analysis: duration of exacerbation
3 days –£14.74 £31.25 –£75.86 to £45.19 –0.00005 0.00009 –0.00022 to 0.00012
BA 3 days –£36.07 £21.10 –£77.11 to £9.67 –0.00005 0.00009 –0.00022 to 0.00012
2 weeks –£14.74 £31.25 –£75.86 to £45.19 –0.00034 0.00030 –0.00093 to 0.00025
BA 2 weeks –£36.07 £21.10 –£77.11 to £9.67 –0.00034 0.00030 –0.00093 to 0.00025
Sensitivity analysis: utility of exacerbation
Utility –£14.74 £31.25 –£75.86 to £45.19 –0.00035 0.00038 –0.00109 to 0.00039
BA utility –£36.07 £21.10 –£77.11 to £9.67 –0.00035 0.00038 –0.00109 to 0.00039
Sensitivity analysis: type of contacts
Respiratory £2.41 £8.65 –£17.58 to £17.26 –0.00008 0.00005 –0.00017 to 0.00001
BA respiratory –£5.06 £5.98 –£18.51 to £5.87 –0.00008 0.00005 –0.00017 to 0.00001
Sensitivity analysis: cost estimation period
5 months £3.74 £14.78 –£25.68 to £32.47 –0.00017 0.00018 –0.00051 to 0.00018
BA 5 months –£6.21 £10.04 –£25.73 to £14.54 –0.00017 0.00018 –0.00051 to 0.00018
Subgroup analysis: under-fives
Under-fives £196.91 £132.94 –£47.60 to £466.99 –0.00102 0.00062 –0.00221 to 0.00020
BA under-fives £35.69 £85.30 –£137.40 to £195.31 –0.00102 0.00062 –0.00221 to 0.00020
a Incremental results are the letter group (1) minus the no-letter group (0).
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In general, the letter intervention was found to be cost-saving, but less effective than no letter at the mean
point estimate. However, all QALY and costs estimates were surrounded by large amounts of uncertainty.
In order to give these results some context based on a hypothetical population of 100,000 people, the
mean point estimates from the adjusted main analysis suggest that by implementing the letter intervention,
17 QALYs would have to be traded against a cost saving of £3,607,000 by decision-makers if the letter
was implemented for 1 year, but with 95% confidence that the intervention may result in a loss of up to
51 QALYs or a gain of up to 18 QALYs and in a cost saving of up to £7,711,000 or an additional cost of
up to £967,000.
Summary of key results from the cost-effectiveness, sensitivity and subgroup analyses
The cost-effectiveness analysis found that there is considerable uncertainty regarding the impact of the
letter intervention on both benefits to patients and costs falling on the NHS. Although the adjusted
base-case analysis showed a mean cost saving of £36.07 per patient and a mean QALY loss of 0.00017,
the CIs around each were wide and did not demonstrate significantly significant differences. The
differences in costs and QALYs from the bootstrapped analysis can also be visually interpreted from the
cost-effectiveness planes for the unadjusted and adjusted main analyses as presented in Figures 23 and 24,
respectively. While the intervention was cost-saving in 96.3% of samples, it also resulted in a QALY loss in
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FIGURE 24 Cost-effectiveness plane for the letter intervention vs. no letter from the BA main analysis.
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FIGURE 23 Cost-effectiveness plane for the letter intervention vs. no letter from the main analysis.
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82.9% of samples (Table 23 and Figure 24). Overall, the intervention was found to be cost-effective in
93.8% of samples when valuing a QALY at £20,000 (see Table 23 and the cost-effectiveness acceptability
curve for the unadjusted and adjusted main analysis in Figure 25).
The very small QALY loss means that the incremental cost-effectiveness ratio (ICER) is very large for all the
analyses. For example, for the adjusted main analysis, the ICER based on the mean point estimates was
£597,103 (SE from the bootstrapped estimations: £187,787) per QALY, which is the ICER for the cost
savings per QALY forgone, rather than the slightly more common cost per QALY gained associated with
reported ICERs. The intervention was dominated (the letter intervention was more costly and less effective
TABLE 23 Mean (SE) ICER, percentage of ICERs in each quadrant of the cost-effectiveness plane, and probability of
cost-effectiveness for main analysis, adjusted analysis and sensitivity analysis
Analysis
(1–0)a
Mean (SE) ICERb
[£/QALY]
ICERs by cost-effectiveness plane quadrant (%)
Percentages of
cost-effectiveness at
λ<willingness to
pay (%)
South-east South-west North-east North-west λ< £0 λ< £20,000
Main 88,733 (114,126) 14.6 52.7 2.5 30.2 67.3 63.1
BA main 597,103 (187,787) 17.0 79.3 0.1 3.6 96.3 93.8
Sensitivity analysis: ‘other’ unit cost
Cost Dominated 11.6 26.6 5.5 56.3 38.2 34.6
BA cost 171,716 (167,195) 16.7 73.5 0.4 9.4 90.2 86.5
Sensitivity analysis: duration of exacerbation
3 days 279,489 (288,070) 23.5 43.8 4.3 28.4 67.3 66.0
BA 3 days 683,777 (314,408) 27.6 68.7 0.2 3.5 96.3 95.5
2 weeks 43,121 (112,808) 11.6 55.7 1.8 30.9 67.3 59.9
BA 2 weeks 105,496 (156,183) 13.3 83.0 0.1 3.6 96.3 90.3
Sensitivity analysis: utility of exacerbation
Utility 41,607 (53,125) 14.9 52.4 2.6 30.1 67.3 59.9
BA utility 101,793 (91,714) 17.4 78.9 0.1 3.6 96.3 89.8
Sensitivity analysis: type of contacts
Respiratory Dominated 2.0 35.5 1.9 60.6 37.5 32.5
BA respiratory 65,020 (22,731) 3.4 76.2 0.5 19.9 79.6 70.7
Sensitivity analysis: cost estimation period
5 months Dominated 11.7 29.3 5.4 53.6 41.0 34.2
BA 5 months 37,358 (45,190) 16.1 58.9 1.0 24.0 75.0 62.4
Subgroup analysis: under-fives
Under-fives Dominated 1.4 4.2 2.6 91.8 5.6 4.5
BA under-fives Dominated 2.8 30.6 1.2 65.4 33.4 26.3
Cost-effectiveness plane quadrants are south-east (less costly, more effective), south-west (less costly, less effective),
north-east (more costly, more effective) and north-west (more costly, less effective).
a Incremental results are the letter group (1) minus the no-letter group (0).
b Negative ICERs can indicate an intervention is either dominant (mean ICER in south-east quadrant) or dominated
(mean ICER in north-west quadrant); negative ICERs are not reported, but are instead replaced with a definition of the
intervention being dominant or dominated by the control.
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than no letter at the mean point estimate) when the ‘other’ unit cost was assigned a pooled weighted
cost, when accounting for only ‘respiratory’-related contacts, when restricting the analysis to 5 months
after intervention, and in the under-fives subgroup analysis; however, this was for the unadjusted analysis
and the intervention was not dominated in the adjusted analysis except in the subgroup analysis. No ICER
could be defined as dominant (a scenario in which the letter intervention would be cost-saving and
more effective at the mean point estimate) as a result of this analysis. These ICERs are suggestive of an
intervention that would be generally deemed not cost-effective if effectiveness (QALY gain) was important
for decision-makers.
The sensitivity analyses showed that the cost-effectiveness results were sensitive to the assumptions regarding
the costing of ‘other’ contacts, the duration and utility decrement assigned to a period of exacerbation, the
types of contact included in the analysis, as well as the period of cost-estimation and whether or not the
focus was on 5- to 16-year-olds or under-5-year-olds. The probability of cost-effectiveness in the adjusted
analysis for the 5- to 16-year-olds, however, generally remained above 62% at a willingness-to-pay (WTP)
threshold (λ) of £20,000 and above 75% when focused on the cost savings (rather than effectiveness;
WTP threshold of £0) of the intervention. The probability of cost-effectiveness in the adjusted analysis for the
under 5 years of age was 26.3% (λ < £20,000) or 33.4% (λ < £0). It should also be noted, however, that
none of the sensitivity analyses demonstrated a significant difference in QALYs or costs, so the overall
conclusion is that there is considerable uncertainty around the cost-effectiveness of the letter intervention.
Although there appears to be some discordance between the cost-effectiveness results and the trial’s
primary clinical outcome of proportion of children having an unscheduled contact in September,
the cost-effectiveness results are consistent with the mean contacts per child endpoints, particularly over
the wider time interval.
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FIGURE 25 Cost-effectiveness acceptability curve for the letter intervention vs. no letter. Note that this graph
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the letter intervention from the main analysis (unadjusted) and the baseline cost-adjusted main analysis.
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Chapter 5 Discussion
Main findings
Previous work has shown an increase in the number of unscheduled medical contacts by children in
autumn months (September to December), which may be a result of the start of the new school term.13
By sending a letter in July to remind children (and their parents) of the importance of using their inhaler,
it was hypothesised that the increase may be averted. More specifically, the hope was that a reminder
letter would lead to a greater uptake of inhaler prescriptions in August, that this, in turn, would also lead
to an increased adherence and, finally, that fewer unscheduled medical appointments would be required.
There is evidence of an impact on the first part of this pathway, as the intervention group demonstrated a
higher uptake of prescriptions in August 2013. There was also an increase in scheduled contacts in the
same month in this group. The data are not available to confirm actual medicine use (as quantified by the
medicine possession ratio), and so it is unclear whether or not the increased uptake also translated into
increased use.
The primary end point was unscheduled medical contacts in September 2013, which coincided with the
start of the new school term. There was no evidence of a reduction in the intervention group, but the
finding of a greater number of unscheduled medical contacts (albeit not statistically significant) is
unexpected. We can offer three potential explanations for this.
First, a repeat prescription request may not be dispensed without a review in situations in which the child
has not received a prescription for several months, or in which the parent wishes to discuss the advantages
and/or disadvantages of recommencing treatment that the child has stopped some months before. This
in turn may be classified as an unscheduled contact in the coding algorithm that we used to define contacts
as unscheduled. The evidence to support this is the large increase in unscheduled contacts in the intervention
group in August (relative to the control group). In addition, it seems the longer the time since a patient last
collected a prescription, the higher the likelihood of an unscheduled contact in September in the intervention
group. This implies that patients with more troublesome asthma may be more likely to have collected a
prescription recently; conversely, patients who have not collected a prescription recently may have stopped
their preventative medication and may be seeing their GP to check whether or not it is still necessary.
Second, the letter may have acted inadvertently as a trigger to contact the practice in relation to an
unrelated medical issue they had been meaning to discuss, which may increase the number of contacts in
the short term.
Third, and finally, the data collected at the time may be equivocal in the coding of the contact, leading us
to incorrectly adjudicate certain contacts as unscheduled when the contact was scheduled, a limitation
of routine data that we will return to in the next section; this is a factor that is important for this
intervention, which did increase scheduled contacts in the first instance.
Despite the increase in unscheduled contacts in September, both the total number of contacts per child
(i.e. scheduled plus unscheduled) and unscheduled contacts were lower in the intervention group than in
the control over the extended study period (September–December 2013) and the full year (September 2013–
August 2014). Although the effects were not statistically significantly, the minimal cost associated with the
intervention meant that the intervention was found to have a high probability of being cost-saving overall.
The economic analysis (which used data over a 12-month period from August 2013 to July 2014) estimated
a mean cost saving across the base case of £36.07 per child and 96.3% probability that the intervention is
cost-saving. By contrast, the cost-effectiveness results are suggestive of an intervention that would be
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generally deemed not cost-effective if effectiveness (QALY gain) was important for decision-makers, as it also
resulted in a QALY loss in 82.9% of samples and a mean loss of 0.00017 QALYs.
The small effects observed could be because of the strength of the link between prescription uptake and
unscheduled medical contacts. Around 5–6% more children received a prescription for asthma medication
in August 2013, a difference that, while substantial, may not be sufficient to achieve the postulated 5%
reduction in unscheduled medical contacts that the study was planned to detect. On the other hand, it
could be that the increased prescription uptake could have reduced the severity (and days off school),
which we could not detect from routine health-care data.
Strengths and weaknesses
Strengths and weaknesses of the trial
The primary strength of the trial is its simple and generalisable design, incorporating an intervention that
could be delivered within general practices with minimal cost. The intervention comprised a short letter,
delivered at the start of the school summer holidays, reminding children of the importance of adhering to
their asthma medication. The trial demonstrated that doing so increased the number of children both
requesting a repeat asthma prescription and having a scheduled medical contact (such as an asthma
review) in August without an associated increase in cost. Nevertheless, as noted above [see Secondary
outcomes, Contacts over 12 months (September 2013 to August 2014)], there was (at best) limited
evidence that this translated into an overall reduction of medical contacts.
We believe the risk of methodological bias is low in this study. The designation of contacts as ‘scheduled’,
‘unscheduled’ and ‘irrelevant’ was based on an independent adjudication panel comprising experienced
GPs who were blinded to treatment group.
The main limitations of the trial were those imposed by the use of routinely collected data as the sole data
source. The issues with using routine data are fairly obvious; data that are collected primarily as a record
of medical care may not contain the information needed for a subsequent research question. For the
outcomes evaluated within this trial, there was considerable uncertainty around the adjudication of some
of the contacts as scheduled, unscheduled or irrelevant. Many of the contacts were coded ‘other’ or
otherwise ambiguous, and the GP Adjudication Panel advised that this probably reflected the limited time
available to GPs when summarising the appointment. There were 34,947 such contacts in the data set, out
of 440,429 contacts (109,352 of which were deemed irrelevant). Even if adjudication of all contacts was
feasible, however, some of more detailed fields are withheld as per CPRD policy, with the (understandable)
reason being to safeguard potentially identifiable details contained therein. As a general issue, this
highlights the tension between research ethics and individual rights, which arises in the use of routine data
for research. On the advice of the GP Adjudication Panel, these contacts were coded as unscheduled.
We note that the use of routine data was a strength in some regards. First and foremost, using routine
data substantially reduced the cost of the trial and allowed us to study a relatively large cohort of children.
It is also the only appropriate way to assess the impact of a population-level intervention. If patients were
recruited to a trial of the effect of receiving (or not) a letter, the very process of recruitment would have
been an intervention. It should also be noted that this is the first large-scale trial of its type using routine
CPRD data as the sole source data: issues that arose in the course of this trial may be abated on future
trials as researchers and data providers become more familiar with the practical considerations involved in
the process of data collation, transfer, recoding and analysis. Some specific examples encountered here are
that practices may withdraw from being with CPRD; that prespecified coding for contacts are often not
used; and that some fields are withheld for reasons of data confidentiality. The extent of these had not
been appreciated or accounted for at the design stage of this trial.
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The push for the use of routine data in clinical evaluation seems likely to continue, and it is important that
researchers have appropriate expectations of what is, and what is not, realistic and achievable, when
using these repositories. Practices leaving the CPRD is a particular issue for studies that have a long-term
follow-up as the primary analysis.
Over the course of the study period, 28 practices stopped contributing data to the CPRD as a result of
switching practice computer systems. At the time of the conclusion of the study period, the CPRD was only
able to collect research-usable data from practices using the Vision IT computer system. It should be noted,
however, that the CPRD is working towards being able to collect research data from GP practices using
computer systems other than Vision. Once this work is complete, it should be the case that practices switching
from one computer system to another will be able to continue their participation in trials and studies.
In retrospect, qualitative interviews with key stakeholders, including practice nurses and GPs, as well as a
larger group of children with asthma, may have added a different dimension in both the development and
(suggested) implementation of the intervention.
Strengths and weaknesses of the economic analysis
As with the clinical evaluation, the main limitation of the economic analysis is that it relied solely on routine
data available within the CPRD database. We therefore had to infer the number of exacerbations experienced
by patients, as well as the duration and severity of those exacerbations, from data on health-care resource
use, which required several assumptions. For example, we assumed that any week including one or more
unscheduled health care contacts was an exacerbation week. Under this assumption, two unscheduled
contacts occurring 2 days apart may count as 1 or 2 weeks of exacerbation depending on whether or not
they fall within the same calendar week. This adds further uncertainty to the QALY estimates that is not
quantified within the CIs provided by the bootstrap analysis.
The use in the study of routine data also meant that we had to rely on published estimates for the impact
of asthma exacerbations on children rather than measuring HRQoL in the patients themselves. This was
problematic, as there was a lack of relevant and high-quality data on the impact of exacerbations on
HRQoL for school-aged children. As a result, we decided to use data from adults in the base-case analysis,
but this may not accurately reflect the impact of exacerbations on HRQoL in children, as their experiences
of asthma may differ from those of adults.
Although the CPRD provides comprehensive data on resource use for the costing analysis, a number of
assumptions were needed to classify all the health-care contacts as either scheduled or unscheduled.
We also had difficulty classifying contacts as respiratory related or not, with a large proportion (38%)
remaining unclassified. For this reason, in the costing analysis we included all contacts, whether they could
be classified as respiratory related or not. As the intervention is not expected to have any effect on
non-respiratory-related contacts, our analysis assumes that any difference between the intervention and
comparator arms was a result of a change in respiratory-related contacts. The inclusion of these unrelated
contacts in the costing analysis is likely to have made it harder to detect whether or not there was a true
difference in respiratory-related contacts. We also found that a significant proportion of contacts (10%)
were coded as consultation type ‘other’, which does not provide a clear indication of the activity involved.
We therefore had to make an assumption regarding the type of activity that might be coded this way.
Our sensitivity analysis found that making alternative assumptions regarding contacts coded as ‘other’
made some difference to the likelihood that the intervention was cost-effective, further supporting our
conclusions that the cost-effectiveness of the letter intervention remains uncertain.
The data recorded in the CPRD on the duration of the consultation and the staff members involved in each
consultation were not considered to be robust enough to use for calculating unit costs. Therefore, in
calculating the unit costs for different types of consultation, we had to make assumptions using advice from
our clinical experts regarding the likely staff mix and duration of contact. We also had to make assumptions
regarding the likely severity of asthma exacerbations presenting in primary and secondary care.
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The costing analysis for prescriptions was also problematic, as many of the drugs used in the management
of asthma are available as a large number of different preparations, each with a unique product code.
For example, for salbutamol inhalers alone, 17 unique products were prescribed within the data set.
To keep the prescription cost analysis manageable, we estimated the cost per prescription for the 10 most
commonly prescribed products for each drug. However, this approximation is not expected to have
significantly biased the cost-effectiveness analysis because the absolute cost of most products prescribed in
the management of asthma is low. We did find that the cost of prescriptions was significantly higher
in the year overall for the letter arm, but this was more than offset by cost savings for other activity,
resulting in a statistically non-significant cost-saving for letter compared with no letter overall.
The analysis takes an NHS and PSS perspective for costs and considers the benefits falling on patients
themselves. Although this is the perspective preferred by NICE,35 it excludes the broader impact of asthma
exacerbations on the children themselves, such as reduced educational opportunities due to missed
schooling. It also excludes any impact on parents and carers, such as time off work when children are not
fit enough to attend school.
A strength of this analysis was the ability to control for baseline costs in the BA economic analysis, which is
an important aspect for consideration based on the allocation of patients (and their associated resource
use patterns) to the control and intervention arms of the trial. Although it was shown in Table 17 that
there was no statistically significant difference in overall resource use or costs between the trial arms for
the 12 months post intervention, there was a statistically significant (p < 0.1) difference in overall costs at
baseline (12 months before intervention) between the trial arms (these baseline results are presented in
Appendix 10, Table 40). There are four reasons why the baseline resource use and costs are important for
the BA economic analysis results and their interpretation:
1. A strong predictor of future resource use is past resource use, and it may be more difficult to influence
the resource use habits of high resource users (who are also referred to as frequent attenders in the
empirical literature) and, therefore, the patients in the letter group may have been less influenced by
the intervention than those in the no-letter group may have been if they were allocated to receive
the letter.
2. The letter intervention was allocated to a group of higher resource users, and this is not accounted for
in the unadjusted economic analysis, which accounts only for the incremental difference in costs at the
12-month follow-up. Therefore, the costs of the letter group were already naturally higher in the letter
group, which has an effect on the assessment of the incremental 12-month follow-up costs in this
economic evaluation.
3. In relation to points 1 and 2, high resource users are, by nature, able to have larger changes in resource
use and costs than low resource users, which will influence the incremental difference between groups
when focusing on incremental differences at follow-up (in terms of costs) if these high resource users
are allocated more to one arm of the trial than the other (e.g. reducing the resource use patterns of
healthier patients with low resource use using an intervention will potentially have a much smaller
change than the potential change if the intervention successfully altered the resource use patterns of
unhealthier patients who are high resource users).
4. The higher resource use and costs could actually have been a result of improved (or just more) resource
use recording at the practices allocated to the letter intervention group (note that allocation was at the
practice level, rather than the patient level), which would have resulted in artificially higher costs and
resource use in the letter group.
For the purpose of discussion, it is unclear which of the aforementioned points may have contributed to
the statistically significantly higher resource use and costs for the letter group at baseline; however,
whatever the reason for the difference in costs and resource use between the letter and no-letter group at
baseline and post intervention, this aspect was controlled for in the BA economic analysis. Therefore, there
is reason to consider that the results from the BA economic analysis may be a better representation of the
potential economic benefit of the letter intervention than the unadjusted (observed) economic analysis.
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In this report, both results have been presented in order to allow decision-makers to account for both sets
of results when judging the cost-effectiveness of this intervention; however, without the BA results,
the intervention would seem less cost-effective than it actually may be in practice.
Patient and public involvement input on the trial results
The children and parents fed back that they felt that the saving per individual as a result of the intervention
was an important finding from the study.27 Their feedback was that this should be emphasised more in the
reporting of the result. We had the children and parents involved throughout, but this input was from
October 2015.
A key point that came from the feedback was the question of whether the results would have been different
if the study had been conducted over a 3-year period rather than 1 year. The parents felt that if the letter
was something they expected each summer it could help in their planning for the start of the school year.
The trial in context: other studies and differences in results
We have not identified any other studies that have examined the economic benefits of a simple postal
intervention in asthma patients and, therefore, it is difficult to compare our results with those of existing
published studies. Yong and Shafie43 have published a systematic review that looked more broadly at
non-pharmacological interventions aiming to improve asthma management. The interventions included by
Yong and Shafie varied from educational and self-management interventions to environmental interventions.
While the PLEASANT study intervention letter could be considered a simple form of patient education, the
educational interventions included by Yong and Shafie were all more intensive, and the population was not
restricted to school-aged children, making comparisons difficult. However, the broader evidence reviewed
by Yong and Shafie suggests that non-pharmacological interventions that aim to improve individuals’
management of their asthma have the potential to be cost-effective.
Meaning of the study and implications for clinicians or policy-makers
The intervention in the PLEASANT study caused an increase in prescription collection in August, as well as
an increase in scheduled medical contacts. It also had the effect of increasing medical contacts in August
and September. After September, there was evidence of a fall in medical contacts, which, although not
statistically significant, did follow through in the economic analysis to give a high probability of the
intervention being cost-saving.
The increase in prescriptions and scheduled contacts in August could lead to individual GP practices
wishing to implement the intervention. Evidence from the trial suggests that this would not increase overall
costs associated with the asthma management, and may improve scheduled care. However, the evidence
from the PLEASANT study is not sufficient to support a general recommendation for all GP practices.
Recommendations for future research
An objective of the study was to increase the take-up of prescriptions in August, as well as the adherence
of children with asthma to taking their medications. The study was not able to assess the latter aspect.
Using routine data has many advantages in terms of trial efficiency in assessing public health or
population-level interventions or in the assessment of proven interventions in real-world settings.
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Our analysis of the PLEASANT study data set suggests that further work is required to determine how to
assess adherence using such data.
A suggested refinement for future trials using routine data could be the inclusion of a prompt for clinicians
to answer study-related questions for patients in the study. For example, if patients enrolled in the study
were to be given a specific study code, then clinicians, when having a consultation with such patients,
could be automatically presented with a template for reporting key data during the study period. For the
PLEASANT study, this would involve asking the clinician one simple question: whether the appointment
was scheduled or not (and perhaps, second, if this was a respiratory-related consultation).
An additional point would be to emphasise to clinicians the importance of ensuring that the routinely
collected patient data needed for the trial are complete, for example, in the PLEASANT study, prescription
data to assess adherence. This could be done through a system prompt.
An investigation of the intervention on emergency contacts (such as out of hours, walk-in centres and
emergency departments) would be of interest.
Future research in assessing interventions to improve adherence in school-aged children with asthma could
include additional qualitative interviews with key stakeholders such as practice nurses, GPs and a wider
group of children with asthma.
A study estimating the impact of asthma exacerbations on school-aged children, using a preference-based
measure of HRQoL that has been validated for use in children, would be useful to inform future
cost-effectiveness analyses.
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Chapter 6 Conclusions
The intervention did not reduce unscheduled care in September, which was the primary end point.However, the intervention succeeded in increasing the proportion of children who collected a
prescription in August, along with the proportion of children who had scheduled contacts in the
same month.
Over a wider time interval, there is weak evidence that the intervention may have reduced medical
contacts. This is reflected in the health economic evaluation, which, overall, showed that the intervention
had a high probability of giving a cost saving. However, there was no associated increase in QALYs.
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Appendix 1 Trial intervention
GP letterhead
<Address line 1>
<Address line 2>
<Address line 3>
<Address line 4>
<Insert Date>
Dear Parent
Please read this important letter regarding your child’s asthma
It is really important that your child continues to take their asthma medication during the summer holidays.
Returning to school is a time when asthma can get worse and make children and young people with
asthma poorly. This may be due to contact with infections at the start of the new school year.
To reduce the chances of getting poorly when they return to school, your child should continue to take
their asthma medication as prescribed by their GP or practice nurse. If your child has stopped taking their
medication over the summer holidays it is important to start it again as soon as possible. If they are short
of medication, or you are not sure of the proper dose, please get in touch with the practice.
Yours sincerely
<Name of Doctor>
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Appendix 2 Changes to protocol
TABLE 24 Changes to the protocol
Changes to protocol Outcome
Research ethics
committee
approval date Approved by
Protocol version 2 (14 May 2015): this version
included an additional secondary outcome to
include data up to September 2014, to see if
the effect from September 2013 is maintained
when there is no study intervention, thus
extending the follow-up period by 1 month
(see Chapter 2, Changes to the data collection,
data extraction and methods for allocation of
data after the trial commenced, with reasons)
Agreed as a 2-month,
non-cost contact
variation by the HTA
programme on
2 February 2015
25 May 2014 National Research Ethics
Service Committee
Yorkshire & The Humber –
South Yorkshire
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Appendix 3 Data management process:
allocation of medical contacts and follow-up data
A ll types of ‘consultation’ are recorded within the data that the CPRD provides. For the purpose of thisstudy, each consultation is considered a medical contact, but not all consultations are considered
relevant to the study. According to the protocol, a scheduled contact is any contact that is part of the
planned care for the patient, for example an asthma review, a medical review, repeat prescription or
immunisation. An unscheduled contact is any unplanned contact that is either patient initiated or is a
result of illness.
Details of how this has been applied and other assumptions to propose the allocation of medical contacts
as ‘scheduled’ and ‘unscheduled’ are described in this appendix.
Data received from the Clinical Practice Research Datalink
Initial test data set received 10 May 2013.
First baseline data set received 19 December 2013.
Second baseline data set received 3 February 2014.
Third baseline data set received 13 July 2014.
Baseline and follow-up data set received 19 January 2015.
Clinical Practice Research Datalink data
Data from the consultation, clinical, immunisation, test, referral and therapy tables from the CPRD Gold
Data dictionary were used.
Overview
Figure 26 shows a very broad overview of how the data have been processed and the number of records.
Full details of assumptions are now described.
General assumptions
One ‘consultation’ (based on the combination of patient ID, practice ID and consultation ID) in the
consultation table is considered one contact.
All consultation data supplied, not just those that are asthma related, are taken into account for the study.
Only consultations that happened on or after 1 August 2012 are included.
Assumptions used to code records as scheduled or unscheduled (contact type) are based on clinical,
immunisation, therapy, referral, test and consultation data.
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Consultation
(consultation n = 1,905,921)
Duplicates removed
(consultation n = 0)
Out of range removed
(consultation n = 1,465,492)
Unique consultation
(consultation n = 440,429) Clinical
(clinical n = 1,755,031)
Unmatched clinical
(clinical n = 1,349,651)
Clinical historical
include/exclude
Code by medcode terms
Unmatched consultation
(consultation n = 258,536)
Matched clinical (with consultation)
(clinical n = 405,380)
Historical excluded
(clinical n = 33,332)
Immunisation
(immune n = 386,678)
Referral
(referral n = 26,524)
Therapy
(therapy n = 1,319,704)
Test
(test n = 254,841)
Matched unmatched
consultation and
unknown clinical with
immunisation, therapy,
referral and test
Matched
immunisation or
scheduled test
(consultation
n = 7483)
Unmatched or
matched with
unknown clinical or
test (consultation
n = 135,390)
Code by consultation
type
Matched therapy,
referral or
unscheduled test
(consultation
n = 107,196)
Code by clinical
consultation type
Match consultation and clinical
Unknown
(clinical 
n = 46,862)
Unscheduled
(clinical 
n = 55,630)
Unscheduled
(consult 
n = 107,198)
Scheduled
(consultation
n = 7483)
Not 
applicable
(clinical 
n = 14,347)
Scheduled
(clinical 
n = 114,685)
Unknown
(clinical 
n = 32,027)
Unscheduled
(clinical 
n = 87,155)
Not 
applicable
(clinical 
n = 21,342)
Scheduled
(clinical 
n = 0)
Unknown
(consultation 
n = 34,842)
Unscheduled
(consultation 
n = 6871)
Not 
applicable
(consultation
n = 83,034)
Scheduled
(consultation
 n = 10,643)
Unknown
(clinical 
n = 78,889)
Unscheduled
(clinical 
n = 142,785)
Not 
applicable
(clinical 
n = 35,689)
Scheduled
(clinical 
n = 114,685)
Not 
coded
(clinical 
n = 140,524)
Scheduled
(consultation n = 71,680)
Unknown
(clinical 
n = 23,648)
Unscheduled
(clinical 
n = 110,487)
Not 
applicable
(clinical 
n = 26,317)
Scheduled
(clinical 
n = 53,554)
Unique on consultation ID
Unscheduled
(consultation n = 259,398)
Not applicable
(consultation n = 109,351)
FIGURE 26 Decision tree showing an overview of how medical contacts have been allocated.
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Records with unmatched event dates
Each consultation record is supplied with an event date; this event date does not always match the event
date recorded for that consultation within the other tables. This is most likely a result of information
entered into the database historically. Those contacts within the clinical table were included if they were
relevant and unlikely to be duplicated (see Inclusion of ‘unmatched/historical’ data section for more
details). All immunisation, therapy, referral and test records that did not match the event date supplied in
the consultation data were excluded.
Clinical data
Clinical data are linked to consultation data, and all matched records are included.
Inclusion of ‘unmatched/historical’ data
If the event date does not match but the clinical event date is within the dates of interest (i.e. from
1 August 2012 to 30 September 2014), then those records that are both relevant and unlikely to be
duplicated are included. The decision on which records to include was made by the GP Adjudication Panel
after reviewing the most common unique terms (10% of the terms, which covered 88% of the data).
The most common 10 terms and the decision of whether or not to include them is shown in Table 25 for
information; rules based on this review were used to decide whether or not to include the 12% of data
not reviewed, for example ‘if it contains seen it is relevant and unlikely to be duplicated’.
Summary of coding using clinical data
The records included are used to determine scheduled or unscheduled contacts based on ‘medcode
description’; the clinical data references Pegasus medical data using the field ‘medcode’ to get ‘medcode
description’. If contact types cannot be determined by ‘medcode description’, then clinical consultation
type ‘constype’ (consultation type) is referenced.
Following GP Adjudication Panel review of the medcode descriptions, in which over 90% of the data were
reviewed (17% of the unique terms), clinical records to be marked as scheduled, unscheduled, not
TABLE 25 Inclusion of ‘unmatched/historical’ data
Medcode_desc Records Flag
Seen in paediatric clinic 5214 Relevant and unlikely to be duplicated
Seen in hospital casualty 4863 Relevant and unlikely to be duplicated
Letter received 2901 Irrelevant
Letter encounter 2654 Irrelevant
Administration 2167 Irrelevant
Seen in orthopaedic clinic 1699 Relevant and unlikely to be duplicated
Letter from consultant 1587 Likely to be duplicated
Letter from specialist 1488 Likely to be duplicated
Discharge summary 1479 Likely to be duplicated
Asthma 1398 Likely to be duplicated
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applicable or unknown were identified based on terms (see Boxes 1–4 and Tables 26 and 27 for examples;
full details are available on request). Based on this review, rules to apply to the data were also determined
(see Table 26). Finally, decisions on how to code the remaining records based on the clinical consultation
type were made (see Table 27).
Conflicting clinical contact types
Clinical data contain more than one record per consultation. In some cases, the same consultation ID can
have more than one clinical contact type. For these clinical records, we assume that unscheduled takes
precedence (i.e. they are likely to have come in for an unscheduled visit but had a scheduled ‘type’ of
procedure at the same time) over all other contact types; that scheduled takes precedence over not
applicable and unknown; and that unknown takes precedence over not applicable.
Clinical to consultation
The code assigned in accordance with clinical contact type as described above is linked to the
consultation data.
Consultation data marked as ‘unknown’ based on the clinical data as well as consultation data that did
not link to clinical data are coded based on immunisation, therapy, referral, test and consultation data as
described in the following sections.
BOX 1 Clinical records: scheduled
Medcode_desc
Administration of medication under patient group direction.
Administration of medication under patient-specific direction.
Antimalarial drug prophylaxis.
Asthma annual review.
Asthma causes daytime symptoms once or twice per month.
Asthma causes daytime symptoms once or twice per week.
Asthma causes daytime symptoms most days.
Asthma causes night-time symptoms once or twice per month.
Asthma causes symptoms most nights.
Asthma causes night waking.
Asthma control questionnaire.
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BOX 2 Clinical records: unscheduled
Medcode_desc
Abdomen examined – NAD.
Abdominal examination – NAD.
Breast examination.
CVS examination.
CVS examined – NAD.
Ear examination – normal.
Emergency appointment.
Examination of cardiovascular system.
Examination of digestive system.
Examination of abdomen.
BOX 3 Clinical records: not applicable
Medcode_desc
[V]Healthy person accompanying sick person.
Advice to GP to change patient medication.
Did not attend – no reason.
Discharged from hospital.
Discharged from accident and emergency.
Discharged from inpatient care.
Drug not collected – no reason.
Employment milestones.
Failed encounter.
Failed encounter – message left on answer machine.
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BOX 4 Clinical records: unknown
Medcode_desc
[V]Issue of repeat prescription.
Advice.
Asthma.
Asthma medication review.
Asthma monitoring due.
Asthma NOS.
Bronchial asthma.
Change in asthma management plan.
Clinical management plan agreed.
Family history.
TABLE 26 Medcode description rules coding
Medcode description Rule
Letter rule If contains ‘letter’ then scheduled, unless it contains ‘referral’; in that case not applicable
Pain/inflamed/sore rule If contains ‘pain’, ‘inflamed’ or ‘sore’, then unscheduled
Asthma trigger rule If contains ‘asthma trigger’ then scheduled, unless it contains ‘infection’; then unscheduled
Immunisation/
vaccination rule
If does not contain ‘letter’ and contains ‘immunisation’, ‘immunisats’, ‘imm’, ‘vacc’ or
‘vaccination’, then scheduled, unless it contains ‘flu’, ‘Influenza’, ‘advice’, ‘not consent’,
‘declined’ or ‘requires’; in that case ‘unknown’
Exam/examination rule If contains ‘exam’ or ‘examination’, then unscheduled, unless it contains ‘chest’, ‘respiratory’,
‘lung’, ‘breath’, ‘foot’ or ‘eye’; then scheduled
Asthma management
plan rule
If contains ‘asthma management plan’ then scheduled, unless it also contains ‘change’ or ‘step
up’; in that case unknown
Referral rule If contains ‘referral’ then not applicable, unless it contains ‘a and e’, ‘accident and emergency’
or ‘admission’; in that case unscheduled
Blank rule If blank, then unscheduled
DNA rule If contains ‘did not attend’ or ‘DNA’, then not applicable
Failed encounter rule If contains ‘failed encounter’, then not applicable
Lloyd George rule If contains ‘Lloyd George’, then not applicable
Seen rule If contains ‘seen’, scheduled, unless it contains ‘accident’, ‘emergency’, ‘out of hours’, ‘GP’,
‘A&E’, ‘rota’, ‘primary care centre’, ‘patient call’, ‘triage’, ‘co-op’, ‘coop’, ‘co op’, ‘walk in’,
‘ooh’, ‘injury’, ‘on call’, ‘home visit’, ‘urgent’, ‘surgery’, ‘doctor’, in which case unscheduled
Out-of-hours rule If contains ‘out of hours’, then unscheduled
Emergency rule If contains ‘emergency’, then unscheduled
Discharge report If contains ‘discharge report’, then unscheduled
DNA, did not attend.
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Immunisation data
Uncoded consultation data are matched against immunisation data; if at least one match is found in the
immunisation record, then these are marked as ‘scheduled’.
Therapy
Those that do not match with immunisation data are linked to medication data. If at least one match is
found, they are marked as ‘unscheduled’.
Referral
Those that do not match with immunisation or therapy data are linked to referral data. If at least one
match is found, they are marked as ‘unscheduled’.
Test
Those that are still uncoded are linked to test. If linked to test it is coded as either ‘scheduled’, ‘unknown’
or ‘unscheduled’ based on a review of the data. In general, if the test is part of the routine asthma review,
then it is coded as ‘scheduled’; if it is testing peak expiratory flow rate then it is coded as ‘unknown’.
Otherwise, it is coded as ‘unscheduled’ (full details are available on request).
When a consultation links to more than one record, the same rules of precedence apply as outlined in the
Conflicting clinical contact types section.
Consultation data
For consultation data that are still ‘unknown’, ‘unlinked’ and, therefore, uncoded, consultation type is used
to determine whether it is scheduled, unscheduled or not applicable (see Table 28 for a summary; full
details are available on request). In this way, all contacts will now be coded as either ‘scheduled’,
‘unscheduled’ or ‘not applicable’.
TABLE 27 Clinical consultation type coding
Clinical consultation type Code as
Administration Not applicable
Symptom Unscheduled
Diagnosis Unscheduled
Intervention Unscheduled
Management Unscheduled
Presenting complaint Unscheduled
Examination Unknown
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Emergency contacts
In addition to coding as scheduled, unscheduled and not applicable, some consultation types from the
consultation table were coded as emergency (Table 29).
TABLE 28 Consultation type coding
Consultation type Coded as
Follow-up/routine visit Scheduled
Repeat issue
Community clinic
Medicine management
If the consultation is about out-of-hours visits, telephone calls,
acute visits, inpatient/hospital admission, accident and emergency
attendance, triage, home/hotel visit, walk-in centre, co-op surgery
or injury
Unscheduled
Clinic Unscheduled (it is assumed that most scheduled
consultation types will be clearly recorded)
Surgery consultation
Other
If the consultation type is ‘Data not entered’, or if it is about
correspondence, reports, administration, nursing/residential home
visits, test results or non-consultation data
Not applicable
TABLE 29 Emergency contact codes
Code Consultation type Relevant medical contact? Unscheduled/scheduled Emergency
2 Night visit, deputising service Yes Unscheduled Yes
4 Night visit, local rota Yes Unscheduled Yes
6 Night visit, practice Yes Unscheduled Yes
7 Out of hours, practice Yes Unscheduled Yes
8 Out of hours, non-practice Yes Unscheduled Yes
11 Acute visit Yes Unscheduled Yes
18 Emergency consultation Yes Unscheduled Yes
20 Casualty attendance Yes Unscheduled Yes
23 Hospital admission Yes Unscheduled Yes
24 Children’s home visit Yes Unscheduled Yes
27 Home visit Yes Unscheduled Yes
28 Hotel visit Yes Unscheduled Yes
32 Twilight visit Yes Unscheduled Yes
34 Walk-in centre Yes Unscheduled Yes
37 Co-op home visit Yes Unscheduled Yes
50 Night visit Yes Unscheduled Yes
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Appendix 4 Statistical analysis plan
 
Project Title: The PLEASANT Study  
(Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a 
New Term)
 
A cluster randomised controlled trial investigating the effect of a postal intervention in reducing 
unscheduled medical contacts in school age children following returning to school. 
 
Statistical Analysis Plan 
Version 1.1.0 
Authored by 
  __________________________________ ___/___/_____ 
  Benjamin Sully    Date  
  PLEASANT trial statistician 
  Medical Statistics Group, DTS, University of Sheffield 
Approved by 
  __________________________________ ___/___/_____ 
  Neil Shephard    Date  
  PLEASANT trial statistician 
  CTRU, DTS, University of Sheffield 
  __________________________________ ___/___/_____ 
  Mike Bradburn     Date 
  PLEASANT trial Senior statistician 
  CTRU, DTS, University of Sheffield 
  __________________________________ ___/___/_____ 
  Professor Steven A. Julious  Date  
  PLEASANT chief investigator 
  Medical Statistics Group, DTS, University of Sheffield 
  __________________________________ ___/___/_____ 
  Martyn Lewis    Date  
  Reader in Biostatistics 
 PLEASANT Trial Steering Committee Statistician 
 Primary Care Sciences, Keele University  
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List of abbreviations used 
AE  Adverse Event 
AFT  Accelerated Failure Time 
CI  Confidence Interval 
CPRD  Clinical Practice Research Datalink 
CTRU  Clinical Trials Research Unit 
GP  General Practitioner 
HTA  Health Technology Assessment 
ICC  Intra-Class Correlation 
ITT  Intent-To-Treat 
MPR  Medicine Possessions Ratio 
NHS  National Health Service 
SOP  Standard Operating Procedure 
TMG  Trial Management Group 
TSC  Trial Steering Committee 
UoS  University of Sheffield 
 
1.1.1 Introduction, study design and key trial objectives 
1.1.1.1  Study outline 
The PLEASANT study is a parallel group, cluster randomised controlled trial that will 
compare a postal intervention to standard care in children aged 4-16 with previous 
diagnoses of asthma; 70 General Practices (GPs) will be randomised to each arm, and 
patients from these GPs will receive the appropriate intervention. 
This statistical analysis plan is written in conjunction with the International 
Conference on Harmonisation topic E9 (Statistical principles for clinical trials), 
applicable standard operating procedures from the Sheffield Clinical Trials Research 
Unit (CTRU) and trial documents referenced in section 4. 
This trial is funded by the National Health Service (NHS) Health Technology 
Assessment (HTA). 
 
1.1.2 Outcome measures 
1.1.2.1  Primary outcome measure 
- The proportion of patients aged between 5-16 who have an unscheduled 
medical contact in September 
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1.1.2.2  Secondary outcome measures 
- The proportion of patients who have an unscheduled medical contact in the 
period September – December 
- The total number of medical contacts (scheduled and unscheduled) per patient 
in September and in the period September – December 
- The time to first unscheduled medical contact in September and in the period 
September – December 
- The proportion of patients who have a medical contact (either scheduled or 
unscheduled) in September and in the period September – December 
- The total number of medical contacts (scheduled and unscheduled) per patient 
in September and in the period September – December 
- The time to first medical contact in September and in the period September – 
December 
- The proportion of patients who have an unscheduled medical contact in 
September and in the period September – December associated with a 
respiratory diagnosis 
- The number of unscheduled medical contacts per patient in September and in 
the period September – December associated with a respiratory diagnosis 
- The time to first unscheduled medical contact associated with a respiratory 
diagnosis in September and in the period September – December 
- The number of prescriptions per patient in the month of August 
- The number of prescriptions in the 12 months following the intervention 
- The proportion of patients who have a scheduled medical contact (for 
example asthma review) in August 
- The proportion of patients who have a scheduled medical contact (for 
example Asthma review) in the 12 months following the intervention. 
All above analyses will be undertaken and reported twice: once on patients under the 
age of 5 and once on patients aged between 5 and 16. This is because asthma is 
difficult to diagnose in children below this age1-2. 
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1.1.2.3  Sample size 
From previous research in the CPRD practice population 30% of school age asthmatic 
children had at least one unscheduled medical contact within the month of 
September13.  We postulate that the intervention may reduce the number of children 
who have unscheduled medical contacts from 30% to 25% (i.e. an absolute reduction 
of 5%).  We would have an effect size of 5%.  The average practice size in the CPRD 
is 8,294.  We thus anticipate circa 100 school age asthmatic patients per practice 
(based on 12% of a practice being school age children and 11% of school age children 
having asthma).  Hence, to detect a difference of 5% with 90% power and two sided 
significance level of 5%, with an intra-class correlation (ICC) of 0.03 to account for 
clustering we require 70 practices per arm.  The sample size of 140 practices would 
equate to approximately 14,000 school age asthmatic patients. 
Ukoumunne et al3 give estimates of ICCs for patients with respiratory symptoms  in 
General Practice.  Based on the work of Ukoumunne et al an ICC of 0.03 is a 
conservative estimate.  The power of the study for ICCs of 0.01, 0.02, 0.03, 0.04 and 
0.05 is respectively 99.4, 96.0, 90.0, 83.1 and 76.2% 
As a further sensitivity analysis we investigated the effect of practices not sending out 
the letter as planned.  Suppose 10 practices failed to send out the letter, these would 
still be included in the primary analysis under the intent to treat principle.  However, 
the effect that could be observed would be reduced to 4.3%.  Under the sample 
assumptions (ICC=0.03 etc) the power for the same sample size is reduced to 79.3%.  
This is a little under 80% but it does demonstrate that the study is reasonably robust to 
at least one deviation in the planned design. 
 
1.1.2.4  Randomisation 
The study is a cluster randomised trial; 70 general practices (GPs) undertaking the 
intervention and 70 control practices of “usual care”. The randomisation will be 
stratified by size of GP to ensure that there is an equal sample size – in terms of 
number of school age asthmatic children – in each arm of the trial. Practices will be 
randomised to one of the two arms after they have agreed to participate. The 
randomisation will be carried out by the University of Sheffield (UoS) Clinical Trials 
Research Unit (CTRU) using a randomisation plan developed prior to the beginning 
of the trial. 
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1.1.2.5  Interim analyses and study committees 
Two committees will be established to govern the conduct of the study: 
1. Trial Management Group (TMG) 
2. Trial Steering Committee (TSC) 
All committees are governed by Sheffield CTRU standard operating procedures. The 
TMG consists of the Principal Investigator, co-investigators and key staff within the 
CTRU. The role of the TMG is to implement all parts of the trial.  
The TSC consists of the Principal Investigator, key staff within the CTRU (as non-
voting members), an independent chair and two independent members (including a 
statistician) and 2 lay members. The roles of the TSC are to provide supervision of the 
protocol and statistical analysis plan, provide advice on and monitor progress of the 
trial. 
No formal interim analyses are required in the study. 
 
1.1.3 Data sources, data evaluability and analysis populations 
1.1.3.1  Data sources 
The data for this study will be collected and managed by the Clinical Practice 
Research Datalink (CPRD), a computerised database of anonymised longitudinal 
medical records from primary care. The CPRD are able to capture all medical contacts 
along with the reason for the contact. 
The PLEASANT study team at CTRU will request and collect the appropriate data 
from CPRD at three time points: 
1. Baseline 
2. 1 month post intervention 
3. 12 months post intervention 
 
The data requested from CPRD will include, for each patient: 
- Age 
- Gender 
- Anonymised General Practice identifier 
- The date of each appointment 
- The type of medical contact for each appointment 
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- The diagnosis given for each appointment 
- Any prescriptions given as a result of an appointment. 
 
1.1.4 Data evaluability 
Upon receiving the data from CPRD, CTRU will handle and prepare the data for 
statistical analysis. This includes forwarding data pertaining to the nature of each 
appointment to an adjudication panel for their review, who will in turn define 
appointments as being either scheduled or unscheduled. The CTRU will also merge 
treatment allocation data with CPRD data and calculate the number of appointments 
for each patient. 
Detailed data management and data quality issues will be set out in a data 
management plan. Data will be retained in accordance with the Data Protection Act 
1998 and CTRU data management Standard Operating Procedures (SOPs). 
All source documents and data will be retained for a period of at least 5 years 
following the end of the trial. 
 
1.1.5 Analysis populations 
The analysis populations will be as follows: 
Intent To Treat (ITT) All randomised patients identified through the extraction 
identified by the CPRD.
Per protocol (PP) The subset of the ITT who belong to a practice which complies to 
the protocol, meet the inclusion/exclusion criteria and whom the 
GPs did not exclude from receiving the intervention.
All analyses will be performed on both study populations.
There are three study periods to be analysed. The primary analysis will be undertaken 
on the primary study period; secondary analyses will use all three stages. 
Primary study period 1st September 2013 – 30th September 2013
Extended study period 1st September 2013 – 31st December 2013
Follow-up period 1st September 2013 – 31st August 2014
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1.1.6 Outline of analyses 
1.1.6.1  General considerations 
Summaries of continuous variables will comprise the sample size used and either: 
i. mean, standard deviation, minimum and maximum, or 
ii. median, inter-quartile range, minimum and maximum 
as appropriate for the distributional form of the data. Summaries of categorical 
variables will comprise the sample size used, and the number and percentage of 
observations in each category. 
 
1.1.6.2  Levels of statistical significance and adjustment for 
multiplicity 
The PLEASANT study was designed and planned using a 2-sided significance level 
of 5%. All analyses will be undertaken using this level of significance. As there is 
only one primary outcome and no interim analysis, adjustment for multiplicity is 
unnecessary.  However adjustments will be made for the multitude of secondary 
outcomes.  Conservative Bonferroni corrections will be made to the raw P-values and 
where possible k-fold cross-validation will be performed by using a leave-one-out 
approach. 
 
1.1.6.3  Rules for derived variables 
The number of appointments for each patient will be calculated after the panel has 
determined whether appointments were scheduled or unscheduled. The numbers of 
each will then be summed (for both the primary and extended study periods).  There 
are instances where no medical code has been used to record the type of medical 
contact and instead free-form text has been entered.  Such entries will always be 
unscheduled (because scheduled contacts are recorded so that GPs are remunerated) 
but it is impossible to determine the nature of the contact and therefore whether it is 
respiratory related or not.  The number of each contact type, in terms of 
“relevant”/”irrelevant”, “scheduled”/”unscheduled”/”unknown” and “respiratory 
related”/”not respiratory related”/”indeterminable” will be reported. 
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The proportion of patients with unscheduled medical contacts in September 2013 will 
be analysed using a derived variable. Any patients who have had one or more 
unscheduled medical contacts in this period will be coded as ‘1’, while those who 
have had zero unscheduled medical contacts in this period will be coded as ‘0’. This 
binary variable will then be used as the dependent variable in the analysis. This will 
be done for all outcomes involving a proportion of patients. 
 
1.1.7 Disposition 
The following summary will be presented for all practices and patients:  
- Centre disposition: the number and percentage of practices included in each 
analysis population with reason for exclusion 
- Patient disposition: the number and percentage of patients included in each 
analysis population with reason for exclusion 
The following summary will be presented for the ITT: 
- Data completeness: the number of patients with complete data for key 
parameters by treatment group 
- Data completeness by practice: the number of patients with complete data for 
key parameters by practice. 
 
1.1.8 Demographics and baseline characteristics 
The following summaries will be presented: 
- Demographics: age; gender; practice; number of asthma admissions in 
September 2012, the period 1st September – 31st December 2012 and the 
period 1st September 2012 – 31st August 2013 (scheduled, unscheduled and 
both combined); time to first medical contact in September and the period 1st 
September – 31st December 2012 (scheduled, unscheduled and both 
combined). 
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1.1.9 Efficacy 
1.1.9.1  Primary outcome 
The primary outcome will be analysed by intent to treat among patients aged 5-16 as 
of 1st September 2012. The primary endpoint (the proportion of patients who have an 
unscheduled medical contact in September) will be analysed by logistic regression in 
which the fixed covariates will include the individual’s age, gender, number of 
contacts the previous September, and trial arm; GP will be included as a random 
effect to account for the effect of clustering by practice. 
The following outputs will be presented for the ITT and PP: 
- The number of unscheduled medical contacts in September 2013 
- The proportion of patients having unscheduled medical contacts in September 
2013 
- The results of the logistic regression modelling for the primary outcome, 
summarising the effect of all covariates fitted in the model. 
 
1.1.10 Secondary outcomes 
1.1.10.1  Proportion of patients with medical contacts 
For analysis of secondary outcomes involving proportions of patients in both the 
extended period of September-December 2013, September2-13-August 2014 and 
September 2014 , the same approach will be used as for the primary outcome. Similar 
covariates will be included in the analysis, ensuring that the baseline variable matches 
the outcome variable. For example, when analysing the proportion of patients who 
have an unscheduled medical contact in the period September – December 2013 
associated with a respiratory diagnosis, the baseline covariate will be the number of 
contacts in the previous September – December 2012 associated with a respiratory 
diagnosis. 
 
1.1.10.2  Number of patients with medical contacts 
For outcomes involving numbers of medical appointments or prescriptions the 
intervention will be analysed in an analogous approach to those involving proportions. 
A random effects negative binomial model will be fitted, including the same 
covariates as above. 
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1.1.10.3  Time to first medical contact 
Analyses involving the time to first medical contact will all be analysed using a 
random effects (“shared frailty”) regression model including the same covariates as 
described previously. Due to the expected high prevalence of ties (i.e. the same time 
to first contact) the Efron method for handling ties will be used. 
 
1.1.11 Number of Prescriptions 
The number of prescriptions per patient in August 2013  and in the 12 months 
following the intervention will also be summarised and analysed under a negative 
binomial random effects regression model. 
 
1.1.11.1  Scheduled contacts 
The proportion of patients who have a scheduled medical contact (e.g. asthma review) 
in August 2013 and in the 12 months following the intervention will be analysed 
using a logistic random effects regression model. 
 
1.1.12 Testing assumptions of statistical analyses 
The primary outcome will be analysed using a random effects logistic regression 
model. This modelling technique is very robust and makes very few assumptions. The 
same applies for the secondary analyses involving proportional dependent variables. 
The Hosmer-Lemeshow test will be used to test the goodness of fit for these models. 
The secondary analyses involving number of events will be analysed using random 
effects negative binomial regression. Similarly to above, this method is very flexible 
and does not rely on assumptions. 
Analyses involving time-to-event data will be analysed using random effects “shared 
frailty” Cox regression. The key assumption underlying this analysis method is that 
the hazard in one group (or one level for a continuous covariate) is a constant multiple 
of that in another group (level). This will be tested by fitting an interaction term 
between time and treatment arm: if the hazard ratio is constant, this term will be non-
significant. If the hazard ratio is found to be non-constant over time the outcome will 
instead be analysed using Accelerated Failure Time (AFT), with goodness of fit 
assessed by Q-Q plots4. If the assumptions underlying this method are not met, 
residual mean survival methods will be used5. 
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1.1.13 Compliance 
Compliance will be based on whether or not practices comply with the intervention 
i.e. whether they send out the letter. To check for differences between complying and 
non-complying practices the demographics for each population will be. Tables 
displaying outcome data will also be reported split by compliance.  
 
1.1.14 Economic analyses 
Economic analyses will be included in a separate document. 
 
1.1.15 Analysis of non-adherence 
In order to identify patients who are non-adherent to regular asthma treatments the 
medicine possessions ratio (MPR) for each participant will be calculated as the 
following: 
 
 
This will be calculated at baseline (the year prior to the intervention) and at follow-up 
(the year following the intervention). Patients with an MPR of under 80% will be 
classed as ‘non-adherent’ to medicine. 
The MPR will be calculated for preventative medications only, using prescription 
information. The analysis will be undertaken only on patients who have a single 
medication which remains the same over both baseline and follow-up; patients 
prescribed more than one preventative medication or who switch medications between 
periods will be excluded from this analysis. 
Informal analysis will take place to ensure that the MPRs are independent across 
treatment arms at baseline and also independent across time points in the control 
group. This will comprise histograms of the MPR and summary statistics. 
The main analysis of MPR will test whether the intervention changes MPR. This will 
be done in two ways: 
1. A test for change in proportion of patients classed as non-adherent before and 
after the intervention in control and intervention arms. 
2. Testing the difference in change in MPR before and after the intervention 
between the control and intervention arms. 
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A separate subgroup analysis will investigate whether patients who are classed as 
non-adherent at baseline respond differently to the intervention to those who are 
classed as adherent. 
1. Paired t-test, intervention group only, comparing difference between baseline 
and follow-up for adherent vs non-adherent. 
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Appendix 5 Systematic review of health-related
quality of life data to inform health economic analysis
This review aimed to identify preference-based utility values for asthma day-to-day symptoms (baselineutility) and asthma exacerbation.
Scoping
A scoping search was conducted to establish the likely quantity and relevance of published literature.
This was done by searching MEDLINE and The Cochrane Library (Cochrane Database of Systematic Review,
HTA database and NHS Economic Evaluation Database) using a limited number of population terms in
addition to a search filter for quality of life. It was found that there was a lack of utility data derived from
EQ-5D in children with asthma. Although EQ-5D is the preferred outcome measure, the standard version of
EQ-5D is not designed to be used with children. EQ-5D-Youth is available for children and adolescents,
but there is not yet a validated UK tariff. In view of this, the NICE reference case states to use other validated
preference-based measures developed for children, but does not specify the preferred quality-of-life
instrument.35 Therefore, a broad approach was taken in the search to identify utility values derived from
EQ-5D, as well as other preference-based measures. EQ-5D values estimated from mapping studies were
also considered.
Search strategy
Search terms
Both free text and medical subject headings (MeSH) pertaining to children, asthma and asthma
exacerbation were used in the search (see Appendix 6). The InterTASC Information Specialists’ Sub-Group
(ISSG) search filter was used to filter studies that report HRQoL (see Appendix 7). The filter was adapted
to include a newly developed preference-based measure for children, Child Health Utility Index 9D,44
as well as other preference-based measures in asthmatic children, such as Asthma Symptom Utility Index.
Full search terms for this review are presented Appendices 6 and 7.
Search limit
The search was not limited by language, publication type, publication dates or study design, with the aim
of increasing sensitivity.
Sources searched
The following clinical and economic databases were searched:
l MEDLINE (via Ovid) (In-Process & Other Non-Indexed Citations) (1946 to 5 July 2014)
l The Cochrane Library (includes Cochrane Database of Systematic Review, NHS Economic Evaluation
Database and HTA database) (up to 5 July 2014)
l EMBASE (1974 to 5 July 2014)
l EconLit (1886 to 5 July 2014)
l School of Health and Related Research (ScHARR) Health Utilities Database (up to 5 July 2014).
In addition to the electronic database search, reference lists of the retrieved papers were screened for
relevant papers.
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Inclusion and exclusion criteria
The inclusion and exclusion criteria for the review are summarised in Table 30. Systematic reviews and
protocols were not included, but were used to identify relevant papers. Modelling studies were examined
to determine the source of utility values used. Modelling studies that described utility data not reported
elsewhere were included in the review.
Selection of studies
In the first stage of study selection, titles and abstracts of the searched results were screened against the
inclusion/exclusion criteria. Full articles were assessed if titles and abstracts were unclear. All studies
identified at titles and abstracts were further screened at full text. The studies were screened by a
single reviewer.
Quality assessment
Quality assessment of articles in this review followed the criteria (sample size, number loss at follow-up and
handling of missing data) recommended by Papaioannou et al.45 in the Decision Support Unit Technical
Support Document on the identification, review and synthesis of health state utility values from the literature.
Data extraction
Data extracted comprised characteristics of study population, study design and details of outcome
measurements (descriptive system, tariff used, method of valuation, time of measurement, mean utility
data and other relevant measures).
TABLE 30 Review inclusion and exclusion criteria
Criteria Inclusion Exclusion
Population l Children with asthma l Asthmatic patients aged ≥ 18 years
l Population with mixed age groups
but including some children
l Non-asthma patients
Intervention l Studies presenting utility data as utility changes
associated with a particular intervention
Outcomes l Utility values from preference-based
measures
l Non-preference-based utility scores unless
mapping to EQ-5D was performed
l Studies that did not publish utility data
Publication type l Qualitative study
l Letters
l Editorials
l Case reports/case series
l Systematic review
l Protocols
Language/others l English-language published papers l Non-English-language published papers
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Selection of utility data for use in the economic analysis
Selection of utility data to use in the economic analysis was based on (1) quality of the study; (2) the
relevance of utility data to the population and health states in the PLEASANT study; and (3) the extent to
which the measurement method was in accordance with the NICE reference case.
Results of systematic review of health-related quality-of-life
data
A total of 927 studies were retrieved from the database search and reference tracking. After removal of
duplicates, 683 studies were screened at titles and abstract. A total of 659 studies were excluded at this
stage (see Appendix 8). Subsequently, 24 papers were screened at full text and 10 papers were excluded,
with reasons given in Appendix 9. Finally, 14 papers were included in this review. Figure 27 shows the
search process of this review.
Study characteristics for the included studies are summarised in Table 31. The study populations are
summarised in Table 32 and methods used to measure HRQoL are summarised in Table 33. Details
regarding study quality are provided in Table 34. Details regarding the suitability of the studies for use in
the economic model, based on the criteria described above, are provided in Table 35.
Potentially
relevant papers
identified through
electronic
databases
(n = 910)
Potentially relevant papers after
removal of duplicates
(n = 683)
Articles screened
at title and abstract
(n = 683)
Full-text articles
assessed for
eligibility
(n = 24)
Full-text articles excluded
(n = 10)
Number of papers
included
(n = 14)
Articles excluded
(n = 659)
Additional articles
identified through
reference tracking
(n = 17)
• Articles reported utility changes associated
   with intervention, n = 5
• Articles did not report utility value, n = 3
• Article used EQ-VAS (non-preference based),
   n = 1
• Article obtained utility data from an
   included study (Carrol and Downs, 200955),
   n = 1
FIGURE 27 Flow diagram of search process. EQ-VAS, EuroQol Visual Analogue Scale.
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TABLE 34 Quality assessments of included papers
First author,
year Sample size Number loss at follow-up Methods of handling missing data
Willems et al.,
200736
109 (mixed age
group)
7/109 (four children) Data imputation by using mean for
baseline score, interpolation between
scores and last value carried forward
Powell et al.,
201346
508 children Postal survey response rate: 45%.
228 completed PedsQL™.
89 patients aged over 5 years
completed EQ-5D questionnaires
(46 in magnesium arm and 43 in
placebo)
Multiple imputation by chained equations
was used to impute missing data. In
under-fives the EQ-5D scores were
estimated by mapping from the PedsQL™
scores. EQ-5D scores at time of exacerbation
were mapped subjectively from ASSs
Price et al.,
201147
687 (mixed age
group)
Step 2: 20/326 excluded post
randomisation, 13/306 loss to
follow-up, but 300/306 had some
data post randomisation
Complete data in 218/683 patients
(32%), data available for ≥ 10 out of
13 items: 514/683 (75%). 19% missing
visit 2 EQ-5D data. Complete-case analysis
presented. In addition, imputed case
presented using Rubin’s multiple
imputation
Step 3: 9/361 excluded post
randomisation, 12/352 were lost to
follow-up, but 350/352 had some
data post randomisation
Brusselle et al.,
200948
158 (mixed age
group)
Only 126 of 158 patients had
baseline EQ-5D values and only
67 had EQ-5D data at 1 year
Not reported
Chiou et al.,
200549
72 children Not applicable Not reported
Mittmann et al.,
199950
17,626 household
residents, of whom
229 had asthma
Not relevant as cross-sectional data Not reported
Juniper et al.,
199751
52 children None Complete data sets provided for all
patients
Norman et al.,
201352
EXALT: 404 (mixed
age group)
EQ-5D scores available for 318
(79%) at 31 weeks
Not reported
Briggs et al.,
200638
GOAL: 3416 (mixed
age group)
526 withdrawals, including 111 lost
to follow-up. Reasons were adverse
events, withdrawal of consent,
protocol violation, ineligible for
study, data that could not be
analysed (n= 117)
Not reported
Doull et al.,
200753
GOAL: 3416 (mixed
age group)
526 withdrawals, including 111 lost
to follow-up. Reasons were adverse
events, withdrawal of consent,
protocol violation, ineligible for
study, data that could not be
analysed (n= 117)
Not reported
Rodríguez-
Martínez et al.,
201354
76 parents Not reported Not reported
Carroll and
Downs, 200955
4016 parents,
29 diseases
Not reported Not reported
Brown et al.,
200756
ETOPA: 312 (mixed
age group)
Not reported Imputation method for patient
prematurely withdrawn. Event with zero
duration was assigned if patient did not
experience any event after 7 days of
discontinuation
Gerald et al.,
201057
Utility data based on
study by Chiou et al.49
Utility data based on study by
Chiou et al.49
Utility data based on study by Chiou et al.49
ASS, asthma symptom score; EXALT, Evaluate Xolair for Asthma as Leading Treatment; GOAL, Gaining Optimal Asthma
ControL; PedsQL™, Pediatric Quality of Life Inventory.
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Six studies included UK patients,38,46,47,52,53,56 three of which were multinational studies.38,53,56 Three papers
were from the USA,49,55,57 two were based in Canada50,51 and one each was from the Netherlands,36
Belgium48 and Spain.54 Only the studies by Juniper et al.,51 Chiou et al.49 and Powell et al.46 directly measured
HRQoL in populations confined to children. Chiou et al.49 recruited children aged between 7 and 12 years
with diagnosed asthma of at least mild persistent severity, while Juniper et al.51 studied children with
symptomatic asthma with a mean age of 12 years (range 7–17 years) and Powell et al.46 included children
aged between 2 and 16 years with acute severe asthma. Two studies, by Rodríguez-Martínez et al.54 and
Carroll and Downs,55 elicited preferences from parents regarding health states in children. Other studies
comprised populations with mixed age groups. Of these, the studies by Mittmann et al.50 and Willems et al.36
presented HRQoL data stratified by age.
The populations in the included studies differed in asthma severity and characteristics. Five studies
measured HRQoL using EQ-5D.36,46–48,52 Other studies used outcome measurements, such as the Pediatric
Asthma Health Outcome Measure (PAHOM) (n = 2) and Health Utilities Index Mark 2 (HUI-2) (n = 1) and
Mark 3 (HUI-3) (n = 1). Direct valuation using vignettes was used in two studies. This review also included
three modelling studies,38,53,56 which estimated EQ-5D data from mapping exercises.
The EQ-5D is a generic preference-based measure in which the descriptive systems consist of five
dimensions: mobility, depression/anxiety, self-care, usual activities, pain and discomfort. Each dimension has
three levels of severity, and this gives rise to 243 possible health states described by the EQ-5D. In the UK,
scoring of EQ-5D was based on time trade-off (TTO) in a representative sample of 2997 adults administered
using York Measurement and Valuation of Health TTO protocol. Public preferences were obtained for
43 health states and regression was used to model data for the remaining health states. Utility score from
the algorithm was anchored at ‘1’ for perfect health and ‘0’ for a state equivalent to death.58
Willems et al.,36 Price et al.47 and Powell et al.46 were randomised controlled trials (RCTs) that elicited an
EQ-5D index score using UK preferences, whereas the EQ-5D score in a cohort study by Brusselle et al.48
was based on the Belgian tariff. Norman et al.52 was a modelling study that used EQ-5D data collected
from the Evaluate Xolair for Asthma as Leading Treatment (EXALT) trial. The tariff used in the EXALT study
is not described by Norman et al.,52 but the data are described as being consistent with the NICE reference
case, suggesting that the UK TTO valuation set was used.
In the MAGNEsium Trial In Children (MAGNETIC), Powell et al.46 included a population of children (n = 508)
with severe acute exacerbations, as defined by British Thoracic Society (BTS)/Scottish Intercollegiate
Guidelines Network (SIGN). The MAGNETIC was a prospective, double-blind, multicentre RCT in the UK,
designed to compare efficacy of nebulised magnesium sulphate with usual care. EQ-5D and Paediatric
Quality of Life Inventory (PedsQL™) postal questionnaires were collected at 1 month post exacerbation.
EQ-5D data were obtained for children aged ≥ 5 years and were filled out by parents as proxy, while
PedsQL™ were obtained for all children and were self-completed if children were over 5 years. Respondents
were asked to recall events in the previous 4 weeks while filling out the outcome measures. The adult UK
tariff was applied to EQ-5D to obtain utility value for each child. Utility values for patients under 5 years
were estimated through mapping between EQ-5D and PedsQL™. In this study, baseline EQ-5D data
during exacerbation were not collected for ethical reasons. Therefore, asthma symptom scores (ASSs) at
exacerbation were mapped to EQ-5D based on experts’ opinions. The expert team comprised a paediatric
consultant and two respiratory nurses who routinely treated asthmatic paediatric patients. An EQ-5D health
state of 11111 was assigned to ASSs of 1–3 in the base case, while ASSs of 4–6 and 7–9 were mapped to
EQ-5D health states of 22222 and 33333, respectively. In our opinion, the subjective nature of this mapping
between ASS and EQ-5D was considered to make the EQ-5D scores estimated at the time of exacerbation
very uncertain. Furthermore, these data would be relevant only to the subgroup of patients who have severe
acute exacerbations requiring treatment in secondary care, as this was the population recruited into the
MAGNETIC. This study was blinded to patients, health-care providers and outcome analysts. Therefore, it
had low risk of performance and detection bias. However, the study was subjected to risk of attrition bias
due to the low response rate of EQ-5D questionnaires. The authors addressed this limitation by using a
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mapping function to estimate EQ-5D data for those with PedsQL™ data. This was based on the subset
of patients for whom both PedQL and EQ-5D data were available. Following mapping estimations,
a total of 218 EQ-5D data were available for analysis for the outcome 1 month after exacerbation.
Price et al.47 included patients in the UK aged between 12 and 80 years with poorly controlled asthma at
BTS/SIGN treatment step 2 or 3. The mean age of patients was 44.74 years (SD 16.49 years) at step 2
and 50.02 years (SD 15.93 years) at step 3. In step 2 patients, a leukotriene receptor antagonist was
compared with inhaled corticosteroid. In step 3 patients who were already receiving inhaled corticosteroid,
a leukotriene receptor antagonist was compared with a long-acting β2-agonist. EQ-5D data were directly
measured from patients and were presented by treatment steps and interventions at baseline, 2 months
and 2 years. Utility values were estimated using UK preferences. This RCT had a high retention rate, with
5–10% loss to follow-up. A large proportion (75%) of patients presented with less than four missing data,
and missing data were handled using multiple imputation. This single-blind RCT (n = 687) was robust, with
large sample size, low risk of attrition bias and measured outcomes with EQ-5D. However, utility data
presented were not stratified by age nor related to asthma exacerbations. Therefore, these data lack
applicability to the PLEASANT trial and the health states modelled.
Willems et al.36 used UK preferences to estimate utility scores for asthmatic patients in the Netherlands.
Populations comprised adults (n = 53) and children (n = 56) with mild to moderate asthma [Global Initiative
for Asthma (GINA) states I–III]. EQ-5D questionnaires were filled by carers for children under 12 years and
self-completed for those aged ≥ 12 years. There were only four children lost to follow-up, and various
imputation techniques were applied. Missing baseline scores were imputed with mean scores. Quality of
life scores at baseline (usual care 0.96, nurse monitoring 0.92) were consistent with the good lung
function of the study’s population [mean forced expiratory volume in the first second (FEV1) above 90%
predicted]. However, these results were elicited from a non-UK population, but did use a UK valuation set.
Willems et al.36 did not examine the utility decrement in exacerbation.
Brusselle et al.48 conducted a 1-year cohort study (n = 158) to determine the efficacy and safety of
omalizumab by looking at changes from baseline in a single-arm study. The mean age of the population
studied was 48.17 years (SD 17.18 years) and age ranged from 12 to 83 years. Patients included had poorly
controlled severe allergic asthma (FEV1 < 80% predicted) and past history of exacerbations. The Belgian
tariff was applied to the collected EQ-5D data at baseline and 1 year. Only 126 of 158 patients had baseline
EQ-5D values, and only 67 had EQ-5D data at 1 year. Handling of missing data, however, was not reported.
This tariff was obtained from public preferences in Belgium using the visual analogue scale (VAS) valuation
method.59 However, valuation using VAS is not a choice-based method. In the UK, NICE expressed a
preference of using TTO as the valuation method, and, in the absence of TTO, other choice-based methods
such as subgroup analysis are preferred over VAS.60 Therefore, utility data estimated from this study do not
meet the NICE requirement of using a choice-based valuation method.
Two USA-based studies, by Chiou et al.49 and Gerald et al.,57 used PAHOM, an asthma-specific
preference-based measure designed for children. It consists of a descriptive system with three dimensions:
symptoms, emotions and activity. The symptoms dimension is classified to three levels of severity, while
emotions and activity are dichotomous choices to indicate presence or absence of problems. Unlike EQ-5D
with a recall period of 1 day, respondents are asked to describe health states for the past 7 days using
PAHOM. The utility value of a health state is calculated as the average utility values over 7 days. Preference
weights for PAHOM were elicited from 114 adults in Seattle, WA, USA, who responded for children.
Subgroup analysis and VAS were used to value health states. As not all health states were valued using
subgroup analysis, because of cognitive burden, VAS values were transformed into subgroup analysis
values using relative risk attitude equation.49
Chiou et al.49 measured utility value in 72 children (aged 7–12 years) with diagnosed asthma of at least
mild persistent severity as 0.83 (converted subgroup analysis value). Chiou et al.49 also reported mean VAS
and subgroup analysis values for patients according to asthma severity, with subgroup analysis values of
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0.79 for mild or no symptoms, 0.70 for moderate and 0.28 for severe. A limitation of this study was
the small sample size, which may have affected the accuracy and validity of results, particularly for the
estimates stratified by severity. Values stratified by presence or absence of exacerbation were not reported.
Gerald et al.57 performed a modelling study on different screening strategies for asthma. A decision tree and
Markov models for a cohort of children were constructed. The Markov model consists of five health states:
asthma symptom-free day, symptom days, exacerbation recovery days, emergency department visits and
hospitalisation days. The utility value for each health state was derived using PAHOM. PAHOM states were
allocated to the modelled health states. When several PAHOM states could describe a modelled health state,
utility values of the relevant states were averaged to estimate a single utility value. For example, three or
four PAHOM states were thought to characterise ‘symptom days’ in the model. The utility values of these
states were averaged to derive utility value for ‘symptom days’. The authors highlighted that this approach
may fail to capture valuation of ‘symptom days’ accurately. In our opinion, the subjective nature of this
mapping from modelled health states to PAHOM states reduces the robustness of these utility estimates. In
addition, a general concern regarding PAHOM was that this measure was not validated for its psychometric
properties. Furthermore, validation of the relative risk attitude equation used to derive subgroup analysis
values was not performed.49
Two Canadian-based observational studies used the Health Utilities Index (HUI) as an outcome measure.
Juniper et al.51 studied the minimum skills required by children to complete outcome measurements
unassisted. The Paediatric Asthma Quality of Life Questionnaire, Feeling Thermometer, HUI and direct
valuation were administered to 52 children aged 7–17 years (mean 12 years) with symptomatic asthma
(mean FEV1 85% predicted). The HUI-2 Canadian tariff was applied to obtain utility value. The mean HUI
baseline value for asthma was reported as 0.89 (SD 0.09).
The six-dimensional version of HUI-2 is a common generic outcome measure in children. Each dimension
has 3–5 levels, allowing 8000 unique health states to be defined. The HUI-2 tariff was estimated from a
sample of 293 parents of school children in Ontario, Canada. Valuations were performed using VAS and
three health states were valued with VAS and subgroup analysis. A power function was then derived to
map VAS values to subgroup analysis values, and multiattribute utility theory was used to derive the
valuation functions.58
Mittmann et al.50 conducted a cross-sectional study to measure HRQoL of 20 chronic diseases. The HUI-3
was administered through interview to 17,626 household residents (≥ 12 years) in Canada. HUI-3 is an
adapted version of HUI-2 with additional dimensions and levels. HUI-3 weights were elicited from a
random sample of adults (n = 504) in Ontario, Canada. In this study, however, the HUI-2 scoring algorithm
was used for HUI-3 data. The mean HUI score reported for children (aged 12–19 years) with asthma was
similar to that reported by Juniper et al.51
In measuring and valuing children’s health, NICE is less clear on the preferred instrument, but advises use
of a standardised and validated preference-based measure designed for children. Although HUI is an
example of an instrument that meets the mentioned criteria, the HUI data from these studies may not be
valid, as the study designs lack rigour. First, the small sample size (n = 52) recruited by Juniper et al.51
may introduce inaccuracy to the results. Second, HUI-3 data were inappropriately scored in the study by
Mittmann et al.50 and utility scores estimated were deemed to be provisional by the authors. Furthermore,
neither of these studies reported the utility decrement attributable to asthma exacerbation.
Four modelling studies performed mapping to estimate EQ-5D values. Brown et al.56 and Norman et al.52
constructed Markov models to evaluate the cost-effectiveness of omalizumab in addition to standard care.
Norman et al.52 used EQ-5D scores measured in the EXALT study for day-to-day asthma symptoms. The
EXALT study was an open-label RCT, comprising 404 patients in the UK (age range from 12 to 75 years)
with poorly controlled severe allergic asthma (FEV1< 80% predicted). Utility for day-to-day symptoms
(by treatment arm) was estimated from EQ-5D scores recorded in the EXALT study.
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Norman et al.52 also conducted a systematic review of HRQoL literature to identify HRQoL data of relevance
to both adult and paediatric populations. In their base-case analysis they used data from Lloyd et al.,37 a
study conducted in an adult population that provides estimates of the health utility decrement (loss)
associated with exacerbations requiring oral steroid treatment and exacerbations requiring hospitalisation.
The decrement was measured by comparing baseline EQ-5D values with those reported at 4 weeks for
patients who did and did not experience exacerbations during that 4-week period. They cited another study
by Steuten et al.,61 which also provided utility values for exacerbations in an adult population. However, this
study collected data at 3- to 6-month intervals, which could make it harder to detect the relationship
between short-term exacerbations and health utility than the 4-week interval used by Lloyd et al.37
Brown et al.56 used a published algorithm by Tsuchiya et al.62 to map the mini-Asthma Quality of Life
Questionnaire (AQLQ) scores from the ETOPA trial onto the EQ-5D. The ETOPA trial was a multinational
open-label trial that recruited 312 patients aged between 12 and 73 years (mean > 35 years) with poorly
controlled allergic asthma (mean FEV1 < 73% predicted).63 (Note that Brown et al.56 used data from the
subgroup of ETOPA patients with severe disease, but baseline characteristics are not described for this
subgroup, so Table 32 provides characteristics for the ETOPA trial as a whole.) The AQLQ scores were
mapped to EQ-5D for patients separated by disease state and responder status. The mapping algorithm
used by Brown et al.56 was derived from a RCT of 3000 adults in the UK with a wide range of asthma.62
In the RCT used to generate the mapping algorithm, both EQ-5D and AQLQ were collected.64 Domains in
EQ-5D were found to overlap with those in AQLQ, with correlations between 0.56 and 0.65. Six main
mapping models and two supplementary models were derived using the regression method and were
validated using an external data set. However, these mapping functions were associated with large
marginal errors, and should be considered only as second best to direct elicitation of EQ-5D data.58
In the economic modelling study by Brown et al.,56 literature-based estimates were used to model the
decrement associated with exacerbations, as the authors stated that the ETOPA trial collected insufficient
patient quality-of-life data during exacerbations. The literature-based estimates cited by Brown et al.56
appear to be from an earlier publication65 of the study by Lloyd et al.37
The modelling studies by Briggs et al.38 and Doull et al.53 mapped AQLQ scores from the 52-week Gaining
Optimal Asthma ControL (GOAL) trial onto EQ-5D values. The GOAL study was a multinational double-blind
RCT designed to evaluate efficacy of a combination of fluticasone/salmeterol compared with fluticasone in
terms of asthma control. The GOAL study comprised 3416 patients (mean age > 35 years; range 12–80 years)
with uncontrolled asthma (mean FEV1 < 80% predicted) from 44 countries.66 Asthma control in the GOAL trial
was classified as totally controlled, well controlled, not well controlled or exacerbation requiring oral steroid
or secondary care by Briggs et al.38 using the GINA definition. As the GOAL trial collected only AQLQ data,
a mapping function obtained through personal communication with Macran and Kind (no further details
of this communication provided by Briggs et al.38) was used to transform AQLQ scores to EQ-5D values.
Subsequently, the utility value for each asthma control health state was derived using regression. In the
regression model, a UK indicator was added as a dummy variable to adjust for a UK specific-population.
The dependent variable was the utility value, whereas asthma control and the UK indicator were the
independent variables. Both independent variables were found to be significant predictors of quality of life.
The quality-of-life data from this study are of relevance to the PLEASANT trial. However, the mapping function
used in the analysis by Briggs et al.38 was inadequately described by the authors, and a published article
providing more details could not be identified from searches. Therefore, an assessment of mapping
performance was not possible.
Doull et al.53 adapted the analysis by Briggs et al.,38 and reclassified asthma control to ‘symptom free’ and
‘with symptoms’. Totally controlled asthma was classified as ‘symptom free’, while other states were
classified as ‘with symptoms’. The weekly utility in the ‘with symptom’ state was equivalent to the
weighted average of the weekly utility in well controlled, not well controlled and exacerbation health
states from Briggs et al.38 Regression was used to estimate the relationship between asthma control and
quality of life, when quality of life was obtained by mapping AQLQ scores to EQ-5D. Asthma control and
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the UK indicator were entered into the model as the independent variables, while weekly utility was
entered as the dependent variable. Subsequently, utility for the ‘with symptoms’ and the ‘symptoms-free’
health states were estimated from the regression coefficients. As utility data in this study were adapted
from Briggs et al.,38 which mapped AQLQ scores to EQ-5D using the mapping function by Macran and
Kind, the validity of mapped data was likewise not assessable.
The method used in Carroll and Downs55 and Rodríguez-Martínez et al.54 involved valuation of hypothetical
health states by parents. Parents were asked to value health states described in vignettes by imagining their
children affected by those states. Descriptions in vignettes, however, differed across studies. Rodríguez-Martínez
et al.54 developed asthma-specific vignettes based on PAHOM,49 and these were validated by expert opinions,
whereas Carroll and Downs55 developed general descriptions of 29 health states with the inclusion of time as a
factor. Rodriguez-Martinez et al.54 requested parents (n= 76) to value vignettes using subgroup analysis, while
Carroll and Downs55 used subgroup analysis and TTO methods in a sample of 4016 parents (Note that each
parent valued only three of a potential 29 states providing around 415 values per state.) Neither study
constructed vignettes based on rigorous methods such as a focus group. The lack of standardised descriptive
systems of vignettes and different valuation methods also resulted in a lack of comparability of results between
studies. In addition, vignettes are limited to specific descriptions of a condition, and may not fully reflect all
experiences of a patient. Therefore, vignettes do not meet the NICE reference case and are considered of little
value in economic evaluation.60 In view of the various limitations associated with vignettes, utility values from
Carroll and Downs55 and Rodríguez-Martínez et al.54 were not considered suitable for use in the PLEASANT
study economic analysis.
Health state utility values used in the analysis
The utility values used in the economic evaluation by Briggs et al.38 appear to be particularly relevant to our
proposed model structure, as they are reported for relevant health states, including an exacerbation state,
and have been estimated from a trial population that included some children. However, the mapping
algorithm used to convert from the condition-specific HRQoL measure (AQLQ) to the EQ-5D utility score is
not from a published source, and is not described in detail, making it difficult to assess its validity. However,
if the values reported by Briggs et al.38 are taken at face value, they provide an estimate of the utility loss for
exacerbation versus total asthma control of –0.216 (SE 0.007). It is possible that some patients do not have
total asthma control in the absence of an exacerbation and the difference between the utility values for the
exacerbation state and the not well controlled states is smaller, at –0.112. The data from Briggs et al.38
suggest that the utility decrement for exacerbation in the average patient is likely to fall in the range –0.112
to – 0.216. The utility decrements provided by Lloyd et al.37 from an adult population are –0.1 and –0.2 for
exacerbations requiring oral steroids and exacerbations requiring hospitalisation, respectively. It therefore
appears that there is reasonable agreement between the values reported by Briggs et al.38 and Lloyd et al.37
We accept that the estimates provided by Briggs et al.38 and Lloyd et al.37 probably underestimate the
degree of utility loss in children with a severe or life-threatening acute exacerbation during the period of
hospitalisation. This is because the utility values were not measured during the acute exacerbation period
itself. In the MAGNETIC, which estimated utility scores in children attending EDs with severe acute asthma,
the utility was estimated to be reduced from a baseline of 0.88 to 0.516 during the initial acute period,
giving a utility decrement of 0.364. However, in the MAGNETIC, this more severe utility decrement was
only applied until hospital discharge, with the average length of hospital stay being 1 day. If we apply a
decrement of 0.364 for 1 day and assume a loss of 0.2 in the remaining 6 days, the average utility loss
over the whole week of exacerbation (–0.22) would be similar to that reported by Briggs et al.38
Given the uncertainty regarding the mapping algorithm used by Briggs et al.,38 and the previous use of
data from Lloyd et al.37 in a number of published economic evaluations, we decided to use the data from
Lloyd et al.37 in the base-case analysis. The data from Briggs et al.38 have been explored in a sensitivity
analysis using the difference between the total control state and the exacerbation state (–0.216) to
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estimate the quality-of-life decrement from exacerbations. This sensitivity analysis is considered to provide
an upper limit on the utility decrement attributable to exacerbation.
For patients without an exacerbation, we have taken the baseline utility score for the control arm of the
study by Willems et al.,36 as this provides an estimate based on the child version of the EQ-5D valued using
the adult UK TTO valuation set. The population was Dutch children aged 7–18 years with a GINA severity
stage I–III receiving standard outpatient care. The value applied to patients without an exacerbation
will affect the calculation of absolute QALYs in each trial arm, but does not affect the estimation of
incremental QALY gain that goes into the cost-effectiveness ratio. Therefore, the selection of this data
source is less critical than that used to determine the decrement attributable to exacerbations. The data
that have been applied in the model are summarised in Health outcomes.
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Appendix 6 Full search strategy
TABLE 36 Full search strategy
Search database Search terms
MEDLINE/EMBASE 1. exp child/
2. exp adolescent/
3. (adolescen$ or teenager$ or teen$ or preteen$ or pre-teen$ or young$ or
youth or young one$ or paediat$ or pediat$ or child$ or “young
people”).ti,ab.
4. 1 or 2 or 3
5. exp asthma/
6. (asthma$ or (asthma$ adj exacerbate$) or “asthma exacerbation”).ti,ab.
7. 5 or 6
8. 4 and 7
9. quality adjusted life year/
10. quality adjusted life.tw.
11. (qaly$ or qald$ or qale$ or qtime$).tw.
12. disability adjusted life.tw.
13. daly$.tw.
14. health status indicators/
15. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six
or shortform thirtysix or shortform thirty six or short form thirtysix or short
form thirty six).tw.
16. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or
short form six).tw.
17. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or
shortform twelve or short form twelve).tw.
18. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or
shortform sixteen or short form sixteen).tw.
19. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or
shortform twenty or short form twenty).tw.
20. (euroqol or euro qol or eq5d or eq 5d).tw.
21. (eq5d child$ or eq 5d child$ or eq5d-youth or eq-5d-y or EuroQol 5D- Youth
or EQ-5D Youth or eq 5d youth).ti,ab.
22. (chu-9d or chu9d or Child Health Utility Index 9D).tw.
23. (asui or Asthma Symptom Utility Index).tw.
24. (hql or hqol or h qol or hrqol or hr qol).tw.
25. (hye or hyes).tw.
26. health$ year$ equivalent$.tw.
27. health utilit$.tw.
28. (hui or hui1 or hui2 or hui3).tw.
29. disutili$.tw.
30. rosser.tw.
31. quality of wellbeing.tw.
32. qwb.tw.
33. willingness to pay.tw.
34. standard gamble$.tw.
35. time trade off.tw.
36. time tradeoff.tw.
37. tto.tw.
38. (preference-based or preference based).tw.
39. or/9–39
40. 8 and 40
The Cochrane Library (Cochrane
Database of Systematic Review, HTA
and the NHS Economic Evaluation
Database)
#1 MeSH descriptor: [Child] explode all trees
#2 MeSH descriptor: [Adolescent] explode all trees
#3 (adolescen* or teenager* or teen* or preteen* or pre-teen* or young* or
youth or young one* or paediat* or pediat* or child* or ‘young people’):
ti,ab
#4 #1 or #2 or #3
#5 MeSH descriptor: [Asthma] explode all trees
#6 (asthma* or (asthma*adj exacerbate*) or ‘asthma exacerbation’):ti,ab
continued
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TABLE 36 Full search strategy (continued )
Search database Search terms
#7 #5 or #6
#8 #4 and #7
#9 MeSH descriptor: [Quality-Adjusted Life Years] explode all trees
#10 quality adjusted life:ti,ab
#11 (qaly* or qald* or qale* or qtime*):ti,ab
#12 ‘disability adjusted life’:ti,ab
#13 daly*:ti,ab
#14 MeSH descriptor: [Health Status Indicators] explode all trees
#15 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six
or shortform thirtysix or shortform thirty six or short form thirtysix or short
form thirty six):ti,ab
#16 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six
or short form six):ti,ab
#17 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or
shortform twelve or short form twelve):ti,ab
#18 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or
shortform sixteen or short form sixteen):ti,ab
#19 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or
shortform twenty or short form twenty):ti,ab
#20 (euroqol or euro qol or eq5d or eq 5d):ti,ab
#21 (eq5d child* or eq 5d child* or eq5d-youth or eq-5d-y or EuroQol
5D- Youth or EQ-5D Youth or eq 5d youth):ti,ab
#22 (chu-9d or chu9d or Child Health Utility Index 9D)
#23 (‘aql-5d’ or ‘Asthma Quality of Life Utility Index- 5d’ or ‘Asthma Quality of
Life Utility Index- 5 dimension’):ti,ab
#24 (asui or ‘Asthma Symptom Utility Index’):ti,ab
#25 (hql or hqol or h qol or hrqol or hr qol):ti,ab
#26 (hye or hyes):ti,ab
#27 health* year* equivalent*:ti,ab
#28 health utilit*:ti,ab
#29 (hui or hui1 or hui2 or hui3):ti,ab
#30 disutili*:ti,ab
#31 rosser:ti,ab
#32 quality of wellbeing:ti,ab
#33 qwb:ti,ab
#34 willingness to pay:ti,ab
#35 standard gamble*:ti,ab
#36 time trade off:ti,ab
#37 time tradeoff:ti,ab
#38 tto:ti,ab
#39 (‘preference-based’ or ‘preference based’):ti,ab
#40 or/9–39
#41 #8 and #40 in Cochrane Reviews (Reviews and Protocols), Other Reviews,
Technology Assessments and Economic Evaluations
School of Health and Related Research
(ScHARR) Health Utilities Database
1. asthma* or (asthma*adj exacerbate*) or ‘asthma exacerbation’/Any field
EconLit 1. (adolescen$ or teenager$ or teen$ or preteen$ or pre-teen$ or young$ or
youth or young one$ or paediat$ or pediat$ or child$ or ”young
people”).ti,ab.
2. (asthma$ or (asthma$ adj exacerbate$) or “asthma exacerbation”).ti,ab.
3. 1 and 2
4. quality adjusted life.tw.
5. (qaly$ or qald$ or qale$ or qtime$).tw.
6. disability adjusted life.tw.
7. daly$.tw.
8. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six
or shortform thirtysix or shortform thirty six or short form thirtysix or short
form thirty six).tw.
9. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or
short form six).tw.
10. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or
shortform twelve or short form twelve).tw.
11. (euroqol or euro qol or eq5d or eq 5d).tw.
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TABLE 36 Full search strategy (continued )
Search database Search terms
12. (eq5d child$ version or eq 5d child$ version or eq5d-youth or eq-5d-y).tw.
13. (chu-9d or chu9d or Child Health Utility Index 9D).tw.
14. (aql-5d or Asthma Quality of Life Utility Index- 5d or Asthma Quality of Life
Utility Index- 5 dimension).tw.
15. (hql or hqol or h qol or hrqol or hr qol).tw.
16. (hye or hyes).tw.
17. health$ year$ equivalent$.tw.
18. health utilit$.tw.
19. (hui or hui1 or hui2 or hui3).tw.
20. disutili$.tw.
21. rosser.tw.
22. quality of wellbeing.tw.
23. qwb.tw.
24. willingness to pay.tw.
25. standard gamble$.tw.
26. time trade off.tw.
27. time tradeoff.tw.
28. tto.tw.
29. (preference-based or preference based).tw.
30. or/4–29
31. 3 and 30
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Appendix 7 Quality-of-life filter
TABLE 37 Quality of life filter
Source/database Filter
Original quality of life (ISSG):
MEDLINE/EMBASE
1. value of life/
2. quality adjusted life year/
3. quality adjusted life.tw
4. (qaly$ or qald$ or qale$ or qtime$).tw
5. disability adjusted life.tw
6. daly$.tw
7. health status indicators/
8. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or
shortform thirtysix or shortform thirty six or short form thirtysix or short form
thirty six).tw
9. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short
form six).tw
10. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or
shortform twelve or short form twelve).tw
11. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or
shortform sixteen or short form sixteen).tw
12. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or
shortform twenty or short form twenty).tw
13. (euroqol or euro qol or eq5d or eq 5d).tw
14. (hql or hqol or h qol or hrqol or hr qol).tw
15. (hye or hyes).tw
16. health$ year$ equivalent$.tw
17. health utilit$.tw
18. (hui or hui1 or hui2 or hui3).tw
19. disutili$.tw
20. rosser.tw
21. quality of wellbeing.tw
22. quality of wellbeing.tw
23. qwb.tw
24. willingness to pay.tw
25. standard gamble$.tw
26. time trade off.tw
27. time tradeoff.tw
28. tto.tw
29. or/1–28
(A) Adapted quality of life (ISSG):
MEDLINE/EMBASE
1. quality-adjusted life-year/
2. quality-adjusted life.tw.
3. (qaly$ or qald$ or qale$ or qtime$).tw.
4. disability adjusted life.tw.
5. daly$.tw.
6. health status indicators/
7. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or
shortform thirtysix or shortform thirty six or short form thirtysix or short form
thirty six).tw.
8. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short
form six).tw.
9. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or
shortform twelve or short form twelve).tw.
10. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or
shortform sixteen or short form sixteen).tw.
11. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or
shortform twenty or short form twenty).tw.
12. (euroqol or euro qol or eq5d or eq 5d).tw.
13. (eq5d child* or eq 5d child* or eq5d-youth or eq-5d-y or EuroQol 5D- Youth or
EQ-5D Youth or eq 5d youth).ti,ab.
14. (chu-9d or chu9d or Child Health Utility Index 9D).tw.
continued
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TABLE 37 Quality of life filter (continued )
Source/database Filter
15. (aql-5d or Asthma Quality of Life Utility Index- 5d or Asthma Quality of Life Utility
Index- 5 dimension).tw.
16. (asui or Asthma Symptom Utility Index).tw.
17. (hql or hqol or h qol or hrqol or hr qol).tw.
18. (hye or hyes).tw.
19. health$ year$ equivalent$.tw.
20. health utilit$.tw.
21. (hui or hui1 or hui2 or hui3).tw.
22. disutili$.tw.
23. rosser.tw.
24. quality of wellbeing.tw.
25. qwb.tw.
26. willingness to pay.tw.
27. standard gamble$.tw.
28. time trade off.tw.
29. time tradeoff.tw.
30. tto.tw.
31. (preference-based or preference based).tw.
32. or/1–31
(B) Adapted quality of life (ISSG):
Cochrane. QOL FILTER – 4 July
2014
#1 MeSH descriptor: [Quality-Adjusted Life-years] explode all trees
#2 quality-adjusted life:ti,ab
#3 (qaly* or qald* or qale* or qtime*):ti,ab
#4 ‘disability adjusted life’:ti,ab
#5 daly*:ti,ab
#6 MeSH descriptor: [Health Status Indicators] explode all trees
#7 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or
shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty
six):ti,ab
#8 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or
short form six):ti,ab
#9 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or
shortform twelve or short form twelve):ti,ab
#10 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or
shortform sixteen or short form sixteen):ti,ab
#11 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or
shortform twenty or short form twenty):ti,ab
#12 (euroqol or euro qol or eq5d or eq 5d):ti,ab
#13 (eq5d child* or eq 5d child* or eq5d-youth or eq-5d-y or EuroQol 5D- Youth or
EQ-5D Youth or eq 5d youth):ti,ab
#14 (chu-9d or chu9d or Child Health Utility Index 9D)
#15 (‘aql-5d’ or ‘Asthma Quality of Life Utility Index- 5d’ or ‘Asthma Quality of Life
Utility Index- 5 dimension’):ti,ab
#16 (asui or ‘Asthma Symptom Utility Index’):ti,ab
#17 (hql or hqol or h qol or hrqol or hr qol):ti,ab
#18 (hye or hyes):ti,ab
#19 health* year* equivalent*:ti,ab
#20 health utilit*:ti,ab
#21 (hui or hui1 or hui2 or hui3):ti,ab
#22 disutili*:ti,ab
#23 rosser:ti,ab
#24 quality of wellbeing:ti,ab
#25 qwb:ti,ab
#26 willingness to pay:ti,ab
#27 standard gamble*:ti,ab
#28 time trade off:ti,ab
#29 time tradeoff:ti,ab
#30 tto:ti,ab
#31 (‘preference-based’ or ‘preference based’):ti,ab
#32 or/1–31
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Appendix 8 Reasons for exclusion at titles
and abstracts
TABLE 38 Reasons for exclusion at titles and abstracts
Reasons Number of studies excluded
Aged ≥ 18 years 175
Did not publish utility data 197
Non-asthma population 87
Non-English papers 8
Non-preference-based/non-utility measure 158
Publication types 34
Total 659
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Appendix 9 Reasons for exclusion at full texts
TABLE 39 Reasons for exclusion at full texts
Study Reasons for exclusion
Janse A, Sinnema G, Uiterwaal C, Kimpen J, Gemke R.
Quality of life in chronic illness: perceptions of parents
and paediatricians. Arch Dis Child 2005;90:486–91
Used HUI-3, but did not report utility data. Results were
presented as percentage similarity in outcome
measurements between physician and parents
Mo F, Choi BC, Li FC, Merrick J. Using Health Utility Index
(HUI) for measuring the impact on health-related quality
of Life (HRQL) among individuals with chronic diseases.
Sci World J 2004;4:746–57
Used HUI-3, but did not report utility data. Results were
presented as graphical differences of quality of life
between diseases
Willems DC, Joore MA, Nieman FH, Severens JL, Wouters EF,
Hendriks JJ. Using EQ-5D in children with asthma, rheumatic
disorders, diabetes, and speech/language and/or hearing
disorders. Int J Technol Assess Health Care 2009;25:391–9
Used EQ-5D, but did not report utility data. Results were
presented as EQ-5D interclass coefficients and Spearman
coefficients between outcome measures
Burstrom K, Svartengren M, Egmar AC. Testing a Swedish
child-friendly pilot version of the EQ-5D instrument – initial
results. Eur J Public Health 2011;21:178–83
Used direct valuation using EQ-VAS as outcome measure
(non-preference based) in Swedish children
Finnell SM, Carroll AE, Downs SM. Application of classic
utilities to published pediatric cost-utility studies. Acad Pediatr
2012;12:219–28
Utility data were obtained from an included study by
Carroll and Downs55
Brodtkorb TH, Zetterstrom O, Tinghog G. Cost-effectiveness
of clean air administered to the breathing zone in allergic
asthma. Clin Respir J 2010;4:104–10
Utility data were presented as utility changes associated
with intervention
Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A,
Meads C, et al. A systematic review and economic evaluation
of subcutaneous and sublingual allergen immunotherapy in
adults and children with seasonal allergic rhinitis. Health
Technol Assess 2013;17(27)
Smith LJ, Holbrook JT, Wise R, Blumenthal M, Dozor AJ,
Mastronarde J, et al. Dietary intake of soy genistein is
associated with lung function in patients with asthma.
J Asthma 2004;41:833–43
Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L,
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